1
|
González-Celestino A, González-Osorio Y, García-Iglesias C, Echavarría-Iñiguez A, Sierra-Mencía A, Recio-García A, Trigo-López J, Planchuelo-Gómez A, Hurtado ML, Sierra-Martínez L, Ruiz M, Rojas-Hernández M, Pérez-Almendro C, Paniagua M, Núñez G, Mora M, Montilla C, Martínez-Badillo C, Lozano AG, Gil A, Cubero M, Cornejo A, Calcerrada I, Blanco M, Alberdí-Iglesias A, Fernández-de-Las-Peñas C, Guerrero-Peral AL, García-Azorín D. Differences and similarities between COVID-19 related-headache and COVID-19 vaccine related-headache. A case-control study. Rev Neurol 2023; 77:229-239. [PMID: 37962534 PMCID: PMC10831767 DOI: 10.33588/rn.7710.2023063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Indexed: 11/15/2023]
Abstract
INTRODUCTION Headache is a frequent symptom at the acute phase of coronavirus disease 2019 (COVID-19) and also one of the most frequent adverse effects following vaccination. In both cases, headache pathophysiology seems linked to the host immune response and could have similarities. We aimed to compare the clinical phenotype and the frequency and associated onset symptoms in patients with COVID-19 related-headache and COVID-19 vaccine related-headache. SUBJECTS AND METHODS A case-control study was conducted. Patients with confirmed COVID-19 infection and COVID-19-vaccine recipients who experienced new-onset headache were included. A standardised questionnaire was administered, including demographic variables, prior history of headaches, associated symptoms and headache-related variables. Both groups were matched for age, sex, and prior history of headache. A multivariate regression analysis was performed. RESULTS A total of 238 patients fulfilled eligibility criteria (143 patients with COVID-19 related-headache and 95 subjects experiencing COVID-19 vaccine related-headache). Patients with COVID-19 related-headache exhibited a higher frequency of arthralgia, diarrhoea, dyspnoea, chest pain, expectoration, anosmia, myalgia, odynophagia, rhinorrhoea, cough, and dysgeusia. Further, patients with COVID-19 related-headache had a more prolonged daily duration of headache and described the headache as the worst headache ever experienced. Patients with COVID-19 vaccine-related headache, experienced more frequently pain in the parietal region, phonophobia, and worsening of the headache by head movements or eye movements. CONCLUSION Headache caused by SARS-CoV-2 infection and COVID-19 vaccination related-headache have more similarities than differences, supporting a shared pathophysiology, and the activation of the innate immune response. The main differences were related to associated symptoms.
Collapse
Affiliation(s)
| | | | - C García-Iglesias
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | | | - A Sierra-Mencía
- Hospital Clínico Universitario de Valladolid, Valladolid, España
| | - A Recio-García
- Hospital Clínico Universitario de Valladolid, Valladolid, España
| | - J Trigo-López
- Hospital Clínico Universitario de Valladolid, Valladolid, España
| | | | - M L Hurtado
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - L Sierra-Martínez
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - M Ruiz
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - M Rojas-Hernández
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - C Pérez-Almendro
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - M Paniagua
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - G Núñez
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - M Mora
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - C Montilla
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - C Martínez-Badillo
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - A G Lozano
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - A Gil
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - M Cubero
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - A Cornejo
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - I Calcerrada
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - M Blanco
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | - A Alberdí-Iglesias
- Área Básica de Salud de Atención Primaria Valladolid Este, Valladolid, España
| | | | | | - D García-Azorín
- Universidad de Valladolid, Valladolid, España
- Hospital Clínico Universitario de Valladolid, Valladolid, España
| |
Collapse
|
2
|
Torres-Ferrus M, López-Veloso AC, Gonzalez-Quintanilla V, González-García N, Díaz de Teran J, Gago-Veiga A, Camiña J, Ruiz M, Mas-Sala N, Bohórquez S, Gallardo VJ, Pozo-Rosich P. The MIGREX study: Prevalence and risk factors of sexual dysfunction among migraine patients. Neurologia 2023; 38:541-549. [PMID: 37802552 DOI: 10.1016/j.nrleng.2021.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 02/07/2021] [Indexed: 10/10/2023] Open
Abstract
BACKGROUND Migraine attacks have a high impact on daily activities. There is limited research on the burden of migraine on sexual functioning. OBJECTIVE To determine the prevalence of sexual dysfunction in patients with migraine and its relationship with migraine features and comorbidities. METHOD This is a cross-sectional study. We included migraine patients between 18 and 60 years-old from 8 Headache Clinics in Spain. We recorded demographic data and migraine features. Patients fulfilled a survey including comorbidities, Arizona Sexual Experiences Scale, Hospital Anxiety and Depression Scale and a questionnaire about migraine impact on sexual activity. A K-nearest neighbor supervised learning algorithm was used to identify differences between migraine patients with and without sexual dysfunction. RESULTS We included 306 patients (85.6% women, mean age 42.3±11.1 years). A 41.8% of participants had sexual dysfunction. Sexual dysfunction was associated with being female (OR [95% CI]: 2.42 [1.17-5.00]; p<0.001), being older than 46.5 years (4.04 [2.48-6.59]; p<0.001), having chronic migraine (2.31 [1.41-3.77]; p=0.001), using preventive medication (2.45 [1.35-4.45]; p=0.004), analgesic overusing (3.51 [2.03-6.07]; p<0.001), menopause (4.18 [2.43-7.17]; p<0.001) and anxiety (2.90 [1.80-4.67]; p<0.001) and depression (6.14 [3.18-11.83]; p<0.001). However, only female gender, age, menopause and depression were the statistically significant variables selected in the model to classify migraine patients with or without sexual dysfunction (Accuracy [95% CI]: 0.75 (0.62-0.85), Kappa: 0.48, p=0.005). CONCLUSIONS Sexual dysfunction is frequent in migraine patients visited in a headache clinic. However, migraine characteristics or use of preventive medication are not directly associated with sexual dysfunction. Instead, risk factors for sexual dysfunction were female gender, higher age, menopause and depression.
Collapse
Affiliation(s)
- M Torres-Ferrus
- Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
| | - A C López-Veloso
- Neurology Department, Gran Canaria Dr. Negrín University Hospital, Las Palmas de Gran Canaria, Spain
| | | | | | - J Díaz de Teran
- Neurology Department, La Paz University Hospital, Madrid, Spain
| | - A Gago-Veiga
- Neurology Department, La Princesa University Hospital, Madrid, Spain
| | - J Camiña
- Neurology Department, Rotger Clinic, Palma de Mallorca, Spain
| | - M Ruiz
- Neurology Department, San Juan Hospital, Alicante, Spain
| | - N Mas-Sala
- Neurology Department, Althaia Hospital, Red Asistencial Universitaria de Manresa, Spain
| | - S Bohórquez
- Neurology Department, Sabana University, Bogotá, Colombia
| | - V J Gallardo
- Neurology Department, Sabana University, Bogotá, Colombia
| | - P Pozo-Rosich
- Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain
| |
Collapse
|
3
|
Ruiz M, Vo AD, Becker JO, Roose ML. Real-Time PCR to Phenotype Resistance to the Citrus Nematode Tylenchulus semipenetrans Cobb. Plants (Basel) 2023; 12:2543. [PMID: 37447106 DOI: 10.3390/plants12132543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 06/27/2023] [Accepted: 06/28/2023] [Indexed: 07/15/2023]
Abstract
As pest management options, such as nematicides, become more restrictive, developing rootstocks resistant to the citrus nematode is fundamental for citrus production. This study provides an updated methodology to screen for citrus nematode resistance in rootstock-breeding programs. We developed a novel method to extract female citrus nematodes from roots that is suitable for molecular work and a real-time-PCR-based nematode quantification method for Tylenchulus semipenetrans. These procedures allow scaling up screening to high-throughput workflows, increasing the chances of finding rootstock candidates that combine all the desired traits. Our results contribute to the growing literature supporting quantification of nematodes with molecular methods.
Collapse
Affiliation(s)
- Marta Ruiz
- Department of Botany and Plant Sciences, University of California, Riverside, CA 92521, USA
| | - Annie Du Vo
- Department of Botany and Plant Sciences, University of California, Riverside, CA 92521, USA
| | - J Ole Becker
- Department of Nematology, University of California, Riverside, CA 92521, USA
| | - Mikeal L Roose
- Department of Botany and Plant Sciences, University of California, Riverside, CA 92521, USA
| |
Collapse
|
4
|
Guerrero-Jiménez M, Ruiz M, Gutiérrez-Rojas L, Jiménez-Muñoz L, Baca-Garcia E, Porras-Segovia A. Use of new technologies for the promotion of physical activity in patients with mental illness: A systematic review. World J Psychiatry 2023; 13:182-190. [PMID: 37123096 PMCID: PMC10130960 DOI: 10.5498/wjp.v13.i4.182] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Revised: 01/14/2023] [Accepted: 03/21/2023] [Indexed: 04/18/2023] Open
Abstract
BACKGROUND Physical exercise is an underutilized tool for the management of mental disorders. New technologies have made a breakthrough in health care, and one of its possible applications (apps) could be that of customizing exercise programs for special populations, such as patients with mental disorders. However, the app of the so-called e-health to mental health care is still limited.
AIM To know the efficacy of apps to promote physical activity in patients with mental disorders.
METHODS We conducted a systematic review of the PubMed and Embase databases with the aim of exploring the use of new technologies for the enhancement of physical exercise in patients with a psychiatric illness. Following the selection process, 10 articles were included in the review.
RESULTS The most commonly used devices in this type of intervention are wearable devices and web platforms. Good results in terms of effectiveness and acceptability were obtained in most of the studies.
CONCLUSION Our findings suggest that the use of new technologies in mental health represents a feasible strategy with great potential in clinical practice.
Collapse
Affiliation(s)
| | - Marta Ruiz
- Department of Psychiatry, Hospital Rey Juan Carlos, Móstoles 28933, Madrid, Spain
| | | | - Laura Jiménez-Muñoz
- Department of Psychiatry, Hospital Universitario Jiménez Díaz, Madrid 28040, Spain
| | | | | |
Collapse
|
5
|
Labauge P, Créange A, Moreau T, Nouvet-Gire J, Pedespan B, Ruiz M, Martinez M, Castelnovo G. Résultats finaux de TEC-ADHERE : étude non interventionnelle sur la persistance au diméthyl fumarate (DMF) des patients atteints de SEP-RR bénéficiant ou non d’un soutien dans le cadre du programme d’accompagnement OroSEP. Rev Neurol (Paris) 2023. [DOI: 10.1016/j.neurol.2023.01.707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
6
|
Diez M, Andreu M, Tejado I, Pi J, Ruiz M, Ezquerra M, Tejero A. Bone Marrow Degeneration Complicating Severe Anorexia Nervosa. Clin Nutr ESPEN 2023. [DOI: 10.1016/j.clnesp.2022.09.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/28/2023]
|
7
|
De Sèze J, Labauge P, Liblau R, Martinez M, Moreau T, Suchet L, Vermersch P, Ruiz M, Rollot F. Résultats finaux de l’étude LymphoTEC : données en vie réelle sur la reconstitution lymphocytaire chez des patients lymphopéniques traités par diméthylfumarate. Rev Neurol (Paris) 2023. [DOI: 10.1016/j.neurol.2023.01.683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
8
|
Gómez Marco F, Yanega D, Ruiz M, Hoddle MS. Proactive classical biological control of Lycorma delicatula (Hemiptera: Fulgoridae) in California (U.S.): Host range testing of Anastatus orientalis (Hymenoptera: Eupelmidae). Front Insect Sci 2023; 3:1134889. [PMID: 38469513 PMCID: PMC10926463 DOI: 10.3389/finsc.2023.1134889] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Accepted: 02/08/2023] [Indexed: 03/13/2024]
Abstract
Lycorma delicatula (Hemiptera: Fulgoridae), the spotted lanternfly, native to China, invaded and established in the northeast U.S. in 2014. Since this time, populations have grown and spread rapidly, and invasion bridgeheads have been detected in mid-western states (i.e., Indiana in 2021). This invasive pest presents a significant threat to Californian agriculture. Therefore, a proactive classical biological control program using Anastatus orientalis (Hymenoptera: Eupelmidae), a L. delicatula egg parasitoid native to China, was initiated in anticipation of eventual establishment of L. delicatula in California. In support of this proactive approach, the potential host range of A. orientalis was investigated. Eggs of 34 insect species either native or non-native to the southwestern U.S. were assessed for suitability for parasitism and development of A. orientalis. Of the native species tested, 10, 13, and one were Hemiptera, Lepidoptera, and Mantodea, respectively. Of the non-native species, eight Hemiptera and two Lepidoptera were evaluated. Host range tests conducted in a quarantine facility, exposed individually mated A. orientalis females (Haplotype C) to non-target and target (i.e., L. delicatula) eggs in sequential no-choice and static choice experiments to determine suitability for parasitization and development. Additionally, the sex ratio, fertility, and size of offspring obtained from non-target and target eggs were evaluated. Results of host range testing indicated that A. orientalis is likely polyphagous and can successfully parasitize and develop in host species belonging to at least two different orders (i.e., Hemiptera, Lepidoptera) and seven families (Coreidae, Erebidae, Fulgoridae, Lasiocampidae, Pentatomidae, Saturniidae and Sphingidae). Prospects for use of A. orientalis as a classical biological control agent of L. delicatula in the southwestern U.S. are discussed.
Collapse
Affiliation(s)
- Francesc Gómez Marco
- Department of Entomology, University of California, Riverside, CA, United States
| | - Douglas Yanega
- Department of Entomology, University of California, Riverside, CA, United States
| | - Marta Ruiz
- Department of Botany & Plant Sciences, University of California, Riverside, CA, United States
| | - Mark S. Hoddle
- Department of Entomology, University of California, Riverside, CA, United States
- Center for Invasive Species Research, University of California, Riverside, CA, United States
| |
Collapse
|
9
|
Ruiz M, Wilson MP, Randhawa S, Low G. Incidental maternal findings on fetal MRI. Clin Radiol 2023; 78:356-361. [PMID: 36890014 DOI: 10.1016/j.crad.2023.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 02/01/2023] [Accepted: 02/03/2023] [Indexed: 02/18/2023]
Abstract
AIM To evaluate the type and frequency of maternal findings incidentally identified during fetal magnetic resonance imaging (MRI). MATERIALS AND METHODS A retrospective single-centre study was undertaken which included all consecutive fetal MRI studies performed between July 2017 and May 2021 at a tertiary institution. Two fellowship-trained radiologists reviewed the studies independently to determine the type and frequency of incidental maternal findings of both no clinical significance (requiring no further follow-up) and of clinical significance (requiring further follow-up, work-up, and/or management). Differences in acquisition were resolved by two-reader consensus. Non-diagnostic MRI examinations or abdominal MRI examinations indicated for maternal complications were excluded from review. RESULTS A total of 455 consecutive fetal MRI examinations performed in 429 women were included. Mean age was 30 years (SD 5.5 years). At least one incidental maternal finding was identified in 58% (265/455) of studies. Umbilical hernias (35%), maternal hydronephrosis (19%), and maternal hydro-ureter (15%) were the most common. Only two studies (0.5%) showed clinically significant incidental maternal findings (pancreatic pseudocyst and ovarian cyst). CONCLUSIONS Incidental maternal findings are common on fetal MRI but rarely require further follow-up, work-up, and/or management.
Collapse
Affiliation(s)
- M Ruiz
- Department of Radiology and Diagnostic Imaging, University of Alberta, University of Alberta Hospital, Edmonton, Alberta, Canada.
| | - M P Wilson
- Department of Radiology and Diagnostic Imaging, University of Alberta, University of Alberta Hospital, Edmonton, Alberta, Canada
| | - S Randhawa
- Department of Radiology and Diagnostic Imaging, University of Alberta, University of Alberta Hospital, Edmonton, Alberta, Canada
| | - G Low
- Department of Radiology and Diagnostic Imaging, University of Alberta, University of Alberta Hospital, Edmonton, Alberta, Canada
| |
Collapse
|
10
|
Alcoberro L, Moliner P, Vime J, Jiménez-Marrero S, Garay A, Yun S, Pons-Riverola A, Ramos-Polo R, Ras-Jiménez M, Tajes M, Hidalgo E, Calero E, Ruiz M, José-Bazán N, Ferre C, Delso C, Alcober L, Enjuanes C, Comin-Colet J. Breaking the 30-day barrier: Long-term effectiveness of a nurse-led 7-step transitional intervention program in heart failure. PLoS One 2023; 18:e0279815. [PMID: 36749763 PMCID: PMC9904494 DOI: 10.1371/journal.pone.0279815] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Accepted: 12/15/2022] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND AND AIMS Heart failure (HF) programs successfully reduce 30-day readmissions. However, conflicting data exist about its sustained effects afterwards and its impact on mortality. We evaluated whether the impact of a new nurse-led coordinated transitional HF program extends to longer periods of time, including 90 and 180 days after discharge. METHODS AND RESULTS We designed a natural experiment to undertake a pragmatical evaluation of the implementation of the program. We compared outcomes between patients discharged with HF as primary diagnosis in Period #1 (pre-program; Jan 2017-Aug 2017) and those discharged during Period #2 (HF program; Sept 2017-Jan 2019). Primary endpoint was the composite of all-cause death or all-cause hospitalization 90 and 180 days after discharge. 440 patients were enrolled: 123 in Period #1 and 317 in Period #2. Mean age was 75±9 years. There were more females in Period #2 (p = 0.025), with no other significant differences between periods. The primary endpoint was significantly reduced in the HF program group, at 90 [adjusted OR 0.31 (0.18-0.53), p <0.001] and at 180 days [adjusted OR 0.18 (CI 0.11-0.32), p <0.001]. Such a decrease was due to a reduction in cardiovascular (CV) and HF hospitalization. All-cause death was reduced when a double check discharge planning was implanted compared to usual care [0 (0%) vs. 7 (3.8%), p = 0.022]. CONCLUSION A new nurse-led coordinated transitional bundle of interventions model reduces the composite endpoint of all-cause death and all-cause hospitalization both at 90 and 180 days after a discharge for HF, also in high-risk populations. Such a decrease is driven by a reduction of CV and HF hospitalization. Reduction of all-cause mortality was also observed when the full model including a more exhaustive discharge planning process was implemented.
Collapse
Affiliation(s)
- Lidia Alcoberro
- Bellvitge Biomedical Research Institute (IDIBELL), Bio-Heart Cardiovascular Diseases Research Group, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain
| | - Pedro Moliner
- Bellvitge Biomedical Research Institute (IDIBELL), Bio-Heart Cardiovascular Diseases Research Group, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- * E-mail: (PM); (JC-C)
| | - Joan Vime
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Santiago Jiménez-Marrero
- Bellvitge Biomedical Research Institute (IDIBELL), Bio-Heart Cardiovascular Diseases Research Group, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Alberto Garay
- Bellvitge Biomedical Research Institute (IDIBELL), Bio-Heart Cardiovascular Diseases Research Group, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Sergi Yun
- Bellvitge Biomedical Research Institute (IDIBELL), Bio-Heart Cardiovascular Diseases Research Group, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Internal Medicine, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Alexandra Pons-Riverola
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Raúl Ramos-Polo
- Bellvitge Biomedical Research Institute (IDIBELL), Bio-Heart Cardiovascular Diseases Research Group, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Mar Ras-Jiménez
- Bellvitge Biomedical Research Institute (IDIBELL), Bio-Heart Cardiovascular Diseases Research Group, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Internal Medicine, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Marta Tajes
- Bellvitge Biomedical Research Institute (IDIBELL), Bio-Heart Cardiovascular Diseases Research Group, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Encarna Hidalgo
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Esther Calero
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Marta Ruiz
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Nuria José-Bazán
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Carles Ferre
- Emergency Department Short-Stay Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Cristina Delso
- Institut Catala de la Salut, SAP Delta Primary Care Service, El Prat de Llobregat, Barcelona, Spain
| | - Laia Alcober
- Institut Catala de la Salut, SAP Delta Primary Care Service, El Prat de Llobregat, Barcelona, Spain
| | - Cristina Enjuanes
- Bellvitge Biomedical Research Institute (IDIBELL), Bio-Heart Cardiovascular Diseases Research Group, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Josep Comin-Colet
- Bellvitge Biomedical Research Institute (IDIBELL), Bio-Heart Cardiovascular Diseases Research Group, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Department of Cardiology, Community Heart Failure Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain
- Institut Catala de la Salut, SAP Delta Primary Care Service, El Prat de Llobregat, Barcelona, Spain
- * E-mail: (PM); (JC-C)
| |
Collapse
|
11
|
Doneddu PE, Ruiz M, Bianchi E, Liberatore G, Manganelli F, Cocito D, Cosentino G, Benedetti L, Marfia GA, Filosto M, Briani C, Giannotta C, Nobile-Orazio E. A diagnostic score for anti-myelin-associated-glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated-glycoprotein antibody. Eur J Neurol 2023; 30:501-510. [PMID: 35191144 PMCID: PMC10078711 DOI: 10.1111/ene.15296] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 02/10/2022] [Accepted: 02/16/2022] [Indexed: 01/07/2023]
Abstract
BACKGROUND AND PURPOSE A diagnostic score was developed to discriminate anti-myelin-associated-glycoprotein (MAG) neuropathy from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and applied it to patients with atypical anti-MAG neuropathy. METHODS The clinical and electrophysiological features of patients with a diagnosis of typical anti-MAG neuropathy were compared to those of patients with a diagnosis of CIDP. The association of each feature with the diagnosis was assessed in the two groups. Features showing a significant association with the diagnosis were included in a multivariable logistic regression model and adjusted odds ratios were estimated for each feature. A score ranging from 1 to 3 was applied to each feature based on the magnitude of the estimated odds ratios. The score was then applied to patients with a clinical diagnosis of CIDP who also had high anti-MAG antibody titers (CIDP-MAG). RESULTS Thirty-one anti-MAG neuropathy patients, 45 typical CIDP patients and 16 CIDP-MAG patients were included. Scores in anti-MAG antibody patients ranged from 1 to 5 and in CIDP patients from -7 to -1. Using the score, 4/16 CIDP-MAG patients were diagnosed to have anti-MAG neuropathy and 12/16 patients to have CIDP. Response to intravenous immunoglobulin in the CIDP-MAG patients classified as CIDP was similar to that of definite CIDP patients and higher than that of anti-MAG neuropathy patients. CONCLUSIONS Our score allowed an accurate discrimination to be made, amongst patients with anti-MAG antibodies, of those affected by CIDP and the patients with anti-MAG neuropathy. This score may help proper treatment to be chosen for patients with anti-MAG antibodies with a CIDP-like presentation.
Collapse
Affiliation(s)
- Pietro E Doneddu
- Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
| | - Marta Ruiz
- Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
| | - Elisa Bianchi
- Laboratorio di Malattie Neurologiche, IRCCS-Istituto Mario Negri, Milan, Italy
| | - Giuseppe Liberatore
- Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
| | - Fiore Manganelli
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Naples, Italy
| | - Dario Cocito
- Presidio Sanitario Major, Istituti Clinici Scientifici Maugeri, Turin, Italy
| | - Giuseppe Cosentino
- IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy
| | - Luana Benedetti
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy
| | - Girola A Marfia
- Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy
| | - Massimiliano Filosto
- Department of Clinical and Experimental Sciences, NeMO-Brescia Clinical Center for Neuromuscular Diseases, University of Brescia, Brescia, Italy
| | - Chiara Briani
- Neurology Unit, Department of Neuroscience, University of Padova, Padova, Italy
| | - Claudia Giannotta
- Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
| | - Eduardo Nobile-Orazio
- Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy
| |
Collapse
|
12
|
Diaz J, Ruiz M, Udina M, Polls F, Martí D, Bech J. Monitoring storm evolution using a high-density seismic network. Sci Rep 2023; 13:1853. [PMID: 36725876 PMCID: PMC9892581 DOI: 10.1038/s41598-023-28902-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Accepted: 01/27/2023] [Indexed: 02/03/2023] Open
Abstract
Data acquired by a dense seismic network deployed in the Cerdanya basin (Eastern Pyrenees) is used to track the temporal and spatial evolution of meteorological events such as rainfall episodes or thunderstorms. Comparing seismic and meteorological data, we show that for frequencies above 40 Hz, the dominant source of seismic noise is rainfall and hence the amplitude of the seismic data can be used as a proxy of rainfall. The interstation distance of 1.5 km provides an unprecedented spatial resolution of the evolution of rainfall episodes along the basin. Two specific episodes, one dominated by stratiform rain and the second one dominated by convective rain, are analyzed in detail, using high resolution disdrometer data from a meteorological site near one of the seismic instruments. Seismic amplitude variations follow a similar evolution to radar reflectivity values, but in some stratiform precipitation cases, it differs from the radar-derived precipitation estimates in this region of abrupt topography, where radar may suffer antenna beam blockage. Hence, we demonstrate the added value of seismic data to complement other sources of information such as rain-gauge or weather radar observations to describe the evolution of ground-level rainfall fields at high spatial and temporal resolution. The seismic power and the rainfall intensity have an exponential relationship and the periods with larger seismic power are coincident. The time intervals with rain drops diameters exceeding 3.5 mm do not result in increased seismic amplitudes, suggesting that there is a threshold value from which seismic data are no longer proportional to the size of the drops. Thunderstorms can be identified by the recording of the sonic waves generated by thunders, with. Single thunders detected to distances of a few tens of kilometers. As the propagation of these acoustic waves is expected to be strongly affected by parameters as air humidity, temperature variations or wind, the seismic data could provide an excellent tool to investigate atmospheric properties variations during thunderstorms.
Collapse
Affiliation(s)
- J. Diaz
- Geosciences Barcelona - CSIC, Barcelona, Spain
| | - M. Ruiz
- Geosciences Barcelona - CSIC, Barcelona, Spain
| | - M. Udina
- grid.5841.80000 0004 1937 0247Department of Applied Physics – Meteorology, University of Barcelona, Barcelona, Spain
| | - F. Polls
- grid.5841.80000 0004 1937 0247Department of Applied Physics – Meteorology, University of Barcelona, Barcelona, Spain
| | - D. Martí
- Geosciences Barcelona - CSIC, Barcelona, Spain
| | - J. Bech
- grid.5841.80000 0004 1937 0247Department of Applied Physics – Meteorology, University of Barcelona, Barcelona, Spain ,grid.5841.80000 0004 1937 0247Water Research Institute, University of Barcelona, Barcelona, Spain
| |
Collapse
|
13
|
Aparicio B, Ruiz M, Casares N, Silva L, Egea J, Pérez P, Albericio G, Esteban M, García-Arriaza J, Lasarte JJ, Sarobe P. Erratum: Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies. Front Immunol 2023; 14:1172427. [PMID: 36936966 PMCID: PMC10020720 DOI: 10.3389/fimmu.2023.1172427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Accepted: 02/23/2023] [Indexed: 03/06/2023] Open
Abstract
[This corrects the article DOI: 10.3389/fimmu.2022.1044025.].
Collapse
Affiliation(s)
- Belén Aparicio
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Marta Ruiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Noelia Casares
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Leyre Silva
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Josune Egea
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Patricia Pérez
- Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain
| | - Guillermo Albericio
- Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Mariano Esteban
- Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Juan García-Arriaza
- Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain
| | - Juan J Lasarte
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Pablo Sarobe
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| |
Collapse
|
14
|
Aparicio B, Repáraz D, Ruiz M, Llopiz D, Silva L, Vercher E, Theunissen P, Tamayo I, Smerdou C, Igea A, Santisteban M, Gónzalez-Deza C, Lasarte JJ, Hervás-Stubbs S, Sarobe P. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer. Front Immunol 2022; 13:985886. [PMID: 36405725 PMCID: PMC9666480 DOI: 10.3389/fimmu.2022.985886] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Accepted: 10/14/2022] [Indexed: 07/20/2023] Open
Abstract
Immune checkpoint inhibitor (ICI)-based immunotherapy in triple negative breast cancer (TNBC) is achieving limited therapeutic results, requiring the development of more potent strategies. Combination of ICI with vaccination strategies would enhance antitumor immunity and response rates to ICI in patients having poorly infiltrated tumors. In heavily mutated tumors, neoantigens (neoAgs) resulting from tumor mutations have induced potent responses when used as vaccines. Thus, our aim was the identification of immunogenic neoAgs suitable as vaccines in TNBC patients. By using whole exome sequencing, RNAseq and HLA binding algorithms of tumor samples from a cohort of eight TNBC patients, we identified a median of 60 mutations/patient, which originated a putative median number of 98 HLA class I-restricted neoAgs. Considering a group of 27 predicted neoAgs presented by HLA-A*02:01 allele in two patients, peptide binding to HLA was experimentally confirmed in 63% of them, whereas 55% were immunogenic in vivo in HLA-A*02:01+ transgenic mice, inducing T-cells against the mutated but not the wild-type peptide sequence. Vaccination with peptide pools or DNA plasmids expressing these neoAgs induced polyepitopic T-cell responses, which recognized neoAg-expressing tumor cells. These results suggest that TNBC tumors harbor neoAgs potentially useful in therapeutic vaccines, opening the way for new combined immunotherapies.
Collapse
Affiliation(s)
- Belén Aparicio
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - David Repáraz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Marta Ruiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Diana Llopiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Leyre Silva
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Enric Vercher
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Patrick Theunissen
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Ibon Tamayo
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Cristian Smerdou
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Ana Igea
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Marta Santisteban
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- Oncología Médica, Clínica Universidad de Navarra, Pamplona, Spain
| | | | - Juan J. Lasarte
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Sandra Hervás-Stubbs
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Pablo Sarobe
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| |
Collapse
|
15
|
Ruiz M, Vives A, Alvarez V, Diaz I, Zaupa A. Health protection among own account and platform workers during COVID19 in Chile. The PWR project. Eur J Public Health 2022. [PMCID: PMC9594277 DOI: 10.1093/eurpub/ckac131.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Background In the last decades, non-standard employment has grown globally. Especially for own account workers (OAW), this implies the self-management of economic, health and other work-related risks. In the context of COVID19, this management was stressed by lockdowns and the novel health risks imposed by an unknown and highly contagious virus, demanding the incorporation of new knowledge and preventive actions. As part of a six-country multiple case qualitative study on non-standard workers (NSW), we explore their experiences and strategies deployed to protect their health while continuing to work. Methods We performed 40 in-depth interviews to NSWs between October 2020 and February 2021, identified through the PWR online-survey and selected through an intentional sampling strategy according to levels of precarity (high-low), gender (male/female) and age (18-39/40-55). Interviews were analysed through abductive thematic analysis. Results We observed a significant transfer to platform, Uber-like jobs in the delivery of goods during lockdown (n = 7). In the absence of institutional prevention programs and provision of protective equipment, OAWs (n = 13) refer the self-provision of COVID19 prevention to protect themselves and their families while continuing to work, deploying a series of strategies amidst limited understanding of both mode of transmission of the virus and actual effective preventive measures. This had serious consequences for them and their families, expressed in anguish, sense of lack of control, fear, and fragility in the face of a major health risk given their constant potential exposure to the virus, leading to both physical and mental health problems, as well as COVID19 infection. Conclusions The substantial growth worldwide of gig delivery work during lockdowns magnified a pressing public health problem, critically requiring social security for gig and OAWs and the development of more equitable and accessible occupational health for all. Key messages • Substantial growth worldwide of gig delivery work during lockdowns magnified a pressing public health problem. • Social security for gig and OAWs are critically required as well as the development of more equitable and accessible occupational health for all.
Collapse
Affiliation(s)
- M Ruiz
- Institute of Public Health, Universidad Austral de Chile , Valdivia, Chile
| | - A Vives
- Department of Public Health, Pontificia Universidad Católica de Chile , Santiago, Chile
- CEDEUS, Pontificia Universidad Catolica , Santiago, Chile
| | - V Alvarez
- University of Valparaiso Sociology, , Valparaiso, Chile
| | - I Diaz
- Department of Public Health, Pontificia Universidad Católica de Chile , Santiago, Chile
| | - A Zaupa
- Department of Public Health, Pontificia Universidad Católica de Chile , Santiago, Chile
| |
Collapse
|
16
|
Repáraz D, Ruiz M, Silva L, Aparicio B, Egea J, Guruceaga E, Ajona D, Senent Y, Conde E, Navarro F, Barace S, Alignani D, Hervás-Stubbs S, Lasarte JJ, Llopiz D, Sarobe P. Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination. Front Immunol 2022; 13:991311. [PMID: 36300124 PMCID: PMC9589451 DOI: 10.3389/fimmu.2022.991311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 09/26/2022] [Indexed: 11/13/2022] Open
Abstract
Vaccination using optimized strategies may increase response rates to immune checkpoint inhibitors (ICI) in some tumors. To enhance vaccine potency and improve thus responses to ICI, we analyzed the gene expression profile of an immunosuppressive dendritic cell (DC) population induced during vaccination, with the goal of identifying druggable inhibitory mechanisms. RNAseq studies revealed targetable genes, but their inhibition did not result in improved vaccines. However, we proved that immunosuppressive DC had a monocytic origin. Thus, monocyte depletion by gemcitabine administration reduced the generation of these DC and increased vaccine-induced immunity, which rejected about 20% of LLC-OVA and B16-OVA tumors, which are non-responders to anti-PD-1. This improved efficacy was associated with higher tumor T-cell infiltration and overexpression of PD-1/PD-L1. Therefore, the combination of vaccine + gemcitabine with anti-PD-1 was superior to anti-PD-1 monotherapy in both models. B16-OVA tumors benefited from a synergistic effect, reaching 75% of tumor rejection, but higher levels of exhausted T-cells in LLC-OVA tumors co-expressing PD-1, LAG3 and TIM3 precluded similar levels of efficacy. Our results indicate that gemcitabine is a suitable combination therapy with vaccines aimed at enhancing PD-1 therapies by targeting vaccine-induced immunosuppressive DC.
Collapse
Affiliation(s)
- David Repáraz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
| | - Marta Ruiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
| | - Leyre Silva
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
| | - Belén Aparicio
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
| | - Josune Egea
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
| | - Elizabeth Guruceaga
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Daniel Ajona
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Yaiza Senent
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain
| | - Enrique Conde
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Flor Navarro
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
| | - Sergio Barace
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
| | - Diego Alignani
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Sandra Hervás-Stubbs
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
| | - Juan José Lasarte
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Diana Llopiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
| | - Pablo Sarobe
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
- *Correspondence: Pablo Sarobe,
| |
Collapse
|
17
|
Yun Viladomat S, Enjuanes C, Calero-Molina E, Hidalgo E, Jose-Bazan N, Ruiz M, Jimenez-Marrero S, Garay A, Alcoberro L, Ras M, Ramos R, Pons-Riverola A, Moliner P, Comin-Colet J. Usefulness of telemedicine-based heart failure monitoring according to “eHealth literacy” domains: insights from the iCOR randomised controlled trial. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background/Introduction
The potential positive effect of electronic health (eHealth)-based heart failure (HF) monitoring remains uncertain, largely due to the heterogeneity of the studies published to date. A subgroup of patients in which its key role is particularly uncertain is in the “low literacy” or “computer or digital illiterate” patients mainly due to telemedicine (TM)-based strategies have been often discouraged on the basis of a foreseeable limited benefit in them.
Purpose
The aim of this study was to determine the effectiveness of a TM-based managed care solution across literacy levels and information and communications technology (ICT) skills.
Methods
We performed a sub-analysis on the basis of two literacy domains (traditional and computer literacy) encompassed in the definition of “eHealth literacy” to the HF-patients included in the “insuficiència Cardíaca Optimitzaciό Remota” (iCOR) randomised study comparing TM vs. usual care (UC) in HF-patients. The primary study endpoint was the incidence of a non-fatal HF event after 6 months of inclusion. The event rates of primary (the occurrence of non-fatal HF event) and secondary (all-cause hospitalization, all cause death and the composite endpoint combining of allcause death or non-fatal HF events) study endpoints were calculated for each literacy domains and its combination. Cox proportional-hazards regression models were used to evaluate the effect of “eHealth literacy” dimensions, treatment group and the interaction term “eHealth literacy” domains by treatment group on study endpoints, and p-value was used to compare the different curves.
Results
178 patients were analysed (81 TM vs 90 UC). As far as the “traditional literacy” analyses, 65% of patients had only elementary education and the 6% had no literacy qualifications, defining the low-educated subgroup as “lower literacy” (126 patients, 71%). All the other patients were classified in the “middle or higher literacy” (52 patients, 29%) subgroup. Moreover, concerning new technological management, 128 patients (72%) referred presenting moderate to high difficulties in its handling, constituting the “lower ICT skills” subgroup. The remaining 28% (50 patients) were allocated into the “middle or higher ICT skills” subgroup due to their minor handicap in their ICT use.
The beneficial effect of TM compared to UC strategy was consistent across all literacy domains (pvalue for interaction 0.207 and 0.117 respectively). The risk of experiencing a primary event was significantly lower in patients that underwent allocation to the TM arm compared to UC in both clustered in the “lower literacy” (p-value=0.001) (Picture 1) and those allocated to the “lower ICT skills” (p-value=0.001) (Picture 2) subgroup.
Conclusions
Non-invasive eHealth-based HF monitoring tools are effective compared to UC in preventing HF events in the early post-discharge period, regardless of two “eHealth literacy” domains (“traditional and computer literacy”).
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- S Yun Viladomat
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - C Enjuanes
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - E Calero-Molina
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - E Hidalgo
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - N Jose-Bazan
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - M Ruiz
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - S Jimenez-Marrero
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - A Garay
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - L Alcoberro
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - M Ras
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - R Ramos
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - A Pons-Riverola
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - P Moliner
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - J Comin-Colet
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| |
Collapse
|
18
|
Lopez ES, Ruiz M, Blasco V, Vime P, Hernáez M, Sánchez MF, Prados N. Increase of blastocyst rate when environment conditions are improved during handling of oocytes and pre-embryos in an IVF treatment. Reprod Biomed Online 2022. [DOI: 10.1016/j.rbmo.2022.08.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
de Leon-Martinez S, Ruiz M, Parra-Vargas E, Chicchi-Giglioli I, Courtet P, Lopez-Castroman J, Artes A, Baca-Garcia E, Porras-Segovia AA, Barrigon ML. Virtual reality and speech analysis for the assessment of impulsivity and decision-making: protocol for a comparison with neuropsychological tasks and self-administered questionnaires. BMJ Open 2022; 12:e058486. [PMID: 35831051 PMCID: PMC9280903 DOI: 10.1136/bmjopen-2021-058486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
INTRODUCTION Impulsivity is present in a range of mental disorders and has been associated with suicide. Traditional measures of impulsivity have certain limitations, such as the lack of ecological validity. Virtual reality (VR) may overcome these issues. This study aims to validate the VR assessment tool 'Spheres & Shield Maze Task' and speech analysis by comparing them with traditional measures. We hypothesise that these innovative tools will be reliable and acceptable by patients, potentially improving the simultaneous assessment of impulsivity and decision-making. METHODS AND ANALYSIS This study will be carried out at the University Hospital Fundación Jiménez Díaz (Madrid, Spain). Our sample will consist of adults divided into three groups: psychiatric outpatients with a history of suicidal thoughts and/or behaviours, psychiatric outpatients without such a history and healthy volunteers. The target sample size was established at 300 participants (100 per group). Participants will complete the Barratt Impulsiveness Scale 11; the Urgency, Premeditation, Perseverance, Sensation Seeking, Positive Urgency, Impulsive Behaviour Scale; Iowa Gambling Task; Continuous Performance Test; Stop signal Task, and Go/no-go task, three questions of emotional affect, the Spheres & Shield Maze Task and two satisfaction surveys. During these tasks, participant speech will be recorded. Construct validity of the VR environment will be calculated. We will also explore the association between VR-assessed impulsivity and history of suicidal thoughts and/or behaviour, and the association between speech and impulsivity and decision-making. ETHICS AND DISSEMINATION This study was approved by the Ethics Committee of the University Hospital Fundación Jiménez Díaz (PIC128-21_FJD). Participants will be required to provide written informed consent. The findings will be presented in a series of manuscripts that will be submitted to peer-reviewed journals for publication. TRIAL REGISTRATION NUMBER NCT05109845; Pre-results.
Collapse
Affiliation(s)
| | - Marta Ruiz
- Department of Psychiatry, Hospital Universitario Rey Juan Carlos, Mostoles, Spain
| | - Elena Parra-Vargas
- Laboratory of Immersive Neurotechnologies (LabLENI), Universidad Politécnica de Valencia, Valencia, Spain
| | - Irene Chicchi-Giglioli
- Department of Signal Theory and Communications, Universidad Carlos III de Madrid, Getafe, Spain
| | - Philippe Courtet
- Unité de recherche U1061, Institut national de la santé et de la recherche médicale, Paris, France
- Department of Emergency Psychiatry and Acute Care, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | | | - Antonio Artes
- Department of Signal Theory and Communications, Universidad Carlos III de Madrid, Leganés, Spain
| | - Enrique Baca-Garcia
- Department of Psychiatry, Hospital Universitario Rey Juan Carlos, Mostoles, Spain
- Department of Psychiatry, University Hospital Centre Nimes, Nimes, France
- Grupo de Investigación en Psiquiatría Translacional, Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Madrid, Spain
- Department of Psychiatry, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
- Universidad Catolica del Maule, Talca, Chile
- Department of Psychiatry, Madrid Autonomous University, Madrid, Spain
- Department of Psychiatry, General Hospital of Villalba, Villaba, Madrid, Spain
- CIBERSAM (Centro de Investigacion en Salud Mental), Carlos III Institute of Health, Madrid, Spain
- Department of Psychiatry, University Hospital Infanta Elena, Valdemoro, Madrid, Spain
| | - Alejandro Albán Porras-Segovia
- Grupo de Investigación en Psiquiatría Translacional, Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Madrid, Spain
- Division of Psychiatry, Imperial College London, London, UK
| | - Maria Luisa Barrigon
- Department of Psychiatry, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| |
Collapse
|
20
|
Yun S, Enjuanes C, Calero-Molina E, Hidalgo E, José-Bazán N, Ruiz M, Verdú-Rotellar JM, Garcimartín P, Jiménez-Marrero S, Garay A, Ras M, Ramos R, Pons-Riverola A, Moliner P, Corbella X, Comín-Colet J. Usefulness of telemedicine-based heart failure monitoring according to 'eHealth literacy' domains: Insights from the iCOR randomized controlled trial. Eur J Intern Med 2022; 101:56-67. [PMID: 35483994 DOI: 10.1016/j.ejim.2022.04.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 04/03/2022] [Accepted: 04/07/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND The potential positive effect of electronic health (eHealth)-based heart failure (HF) monitoring remains uncertain mainly in the 'low literacy' or 'computer or digital illiterate' patients. The aim of this study was to determine the effectiveness of a telemedicine (TM)-based managed care solution across literacy levels and information and communications technology (ICT) skills. METHODS We performed a sub-analysis on the basis of two literacy domains encompassed in the definition of 'eHealth literacy' to the HF-patients included in the 'insuficiència Cardíaca Optimització Remota' (iCOR) randomized study comparing TM vs. usual care (UC) in HF-patients. The primary study endpoint was the incidence of a non-fatal HF event after 6 months of inclusion. The event rates of primary and secondary study endpoints were calculated for each literacy domains and its combination. Cox proportional-hazards regression models were used to evaluate the effect of 'eHealth literacy' dimensions, treatment group and the interaction term 'eHealth literacy' domains by treatment group on study endpoints. RESULTS The beneficial effect of TM compared to UC strategy was consistent across all literacy domains (p-value for interaction 0.207 and 0.117 respectively). The risk of experiencing a primary event was significantly lower in patients that underwent allocation to the TM arm compared to UC in both clustered in the 'lower literacy' (p-value=0.001) and those allocated to the 'lower ICT skills' (p-value=0.001) subgroup. CONCLUSIONS Non-invasive eHealth-based HF monitoring tools are effective compared to UC in preventing HF events in the early post-discharge period, regardless of two 'eHealth literacy' domains ('traditional and computer literacy').
Collapse
Affiliation(s)
- Sergi Yun
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Cristina Enjuanes
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Esther Calero-Molina
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Encarnación Hidalgo
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Núria José-Bazán
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Marta Ruiz
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - José María Verdú-Rotellar
- Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Jordi Gol Primary Care Research Institute, Catalan Institute of Heath, Barcelona, Spain
| | - Paloma Garcimartín
- Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Chief nursing officers. Hospital del Mar, Parc de Salut Mar, Barcelona, Spain; Escuela Superior de Enfermería del Mar, Parc de Salut Mar, Barcelona, Spain
| | - Santiago Jiménez-Marrero
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Cardio-Oncology Unit. Bellvitge University Hospital and Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona, Spain
| | - Alberto Garay
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Cardio-Oncology Unit. Bellvitge University Hospital and Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona, Spain
| | - Mar Ras
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Raúl Ramos
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Alexandra Pons-Riverola
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Pedro Moliner
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Cardio-Oncology Unit. Bellvitge University Hospital and Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona, Spain
| | - Xavier Corbella
- Department of Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Systemic Diseases and Ageing Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Hestia Chair in Integrated Health and Social Care, School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain
| | - Josep Comín-Colet
- Community Heart Failure Program, Departments of Cardiology and Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, School of Medicine, University of Barcelona (UB), Barcelona, Spain.
| |
Collapse
|
21
|
Simoneau G, Jiang X, Rollot F, Tian L, Copetti M, Guéry M, Ruiz M, Vukusic S, de Moor C, Pellegrini F. Overall and patient-level comparative effectiveness of dimethyl fumarate and fingolimod: A precision medicine application to the Observatoire Français de la Sclérose en Plaques registry. Mult Scler J Exp Transl Clin 2022; 8:20552173221116591. [PMID: 35959484 PMCID: PMC9358343 DOI: 10.1177/20552173221116591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Accepted: 07/12/2022] [Indexed: 11/17/2022] Open
Abstract
Background Comparing real-world effectiveness and tolerability of therapies for
relapsing-remitting multiple sclerosis is increasingly important, though
average treatment effects fail to capture possible treatment effect
heterogeneity. With the clinical course of the disease being highly
heterogeneous across patients, precision medicine methods enable treatment
response heterogeneity investigations. Objective To compare real-world effectiveness and discontinuation profiles between
dimethyl fumarate and fingolimod while investigating treatment effect
heterogeneity with precision medicine methods. Methods Adults initiating dimethyl fumarate or fingolimod as a second-line therapy
were selected from a French registry. The primary outcome was annualized
relapse rate at 12 months. Seven secondary outcomes relative to
discontinuation and disease progression were considered. A precision
medicine framework was used to characterize treatment effect
heterogeneity. Results Annualized relapse rates at 12 months were similar for dimethyl fumarate and
fingolimod. The odd of treatment persistence was 47% lower for patients
treated with dimethyl fumarate relative to those treated with fingolimod
(odds ratio: 0.53, 95% confidence interval: 0.39, 0.70). None of the five
precision medicine scoring approaches identified treatment
heterogeneity. Conclusion These findings substantiated the similar effectiveness and different
discontinuation profiles for dimethyl fumarate and fingolimod as a
second-line therapy for relapsing-remitting multiple sclerosis, with no
significant effect heterogeneity observed.
Collapse
|
22
|
Prados Dodd N, Ruiz M, Hüttelová R, Larsson P, Fernández Sánchez M, Višnová H, Mannaerts B. P-134 The robustness of Gardner and Schoolcraft (GS) scoring prior vitrification for selecting a single vitrified blastocyst for transfer. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Do changes in the GS score before vitrification and before transfer of a single vitrified-warmed blastocyst (SVBT) predict the chance of live birth?
Summary answer
There was no association between changes in GS score and the chance of live birth after SVBT.
What is known already
Morphological scoring of human blastocysts is commonly used for assessing the embryo potential for implantation and live birth. Blastocysts that are vitrified and subsequently warmed are usually observed for re-expansion, which is taken for the decision whether to transfer or if another blastocyst will be warmed. Re-scoring warmed embryos before SVBT may result in a lower, same or higher score and may be applied to select the embryo with the highest quality for transfer.
Study design, size, duration
The GS score was evaluated twice namely before vitrification and immediately before SVBT for 374 embryo transfers in 240 women participating in the RAINBOW trial (NCT03564509). Subjects were stimulated with a fixed individualized daily dose of follitropin delta in a long GnRH agonist protocol. Blastocyst transfer was performed on day 5; remaining blastocysts were cryopreserved on day 5/6.
Participants/materials, setting, methods
The association between changes in GS score from before vitrification to before SVBT was investigated using a mixed effect logistic regression model with factors for expansion and hatching status, inner cell mass, and trophectoderm (with decrease, no change, and increase as factor levels for each), and assuming that the log-odds of achieving a live birth was normally distributed in the trial population.
Main results and the role of chance
A total of 472 embryos were vitrified and scored with the GS grading system before vitrification and before SVBT. Of these 298 (63%) had identical scores before and after vitrification. Changes in expansion and hatching status were seen for 23%, inner cell mass for 21%, and trophectoderm for 21% of embryos. Of the 472 warmed embryos, 32 were discarded and 66 were used for double transfers. The remaining 374 blastocysts were used for single embryo transfers. Of these 374 embryos, 68% had identical GS scores at the two scorings, 12%/6% had increase/decrease in expansion and hatching score, 10%/6% had increase/decrease in inner cell mass grading, and 12%/4% had increase/decrease in trophectoderm grading. There was no statistically significant association between either of these changes and the chance of live birth (expansion and hatching: p = 0.94, inner cell mass: p = 0.71, trophectoderm: p = 0.60).
Limitations, reasons for caution
Only 68 (32%) of the 374 blastocysts had different scores before vitrification and before SVBT, indicating the consistency of the score regardless vitrification. Thus, there was only limited power to show an association with chance of live birth. Also, embryos with low quality after thawing were not used for transfer.
Wider implications of the findings
Selection of vitrified embryos for transfer can be based on the pre-vitrification score, as the post-vitrification quality correlates well with the pre-vitrification quality and potential changes may not affect the chance of live birth
Trial registration number
NCT03564509
Collapse
Affiliation(s)
| | - M Ruiz
- IVI-RMA Seville, Embryology Laboratory , Sevilla, Spain
| | - R Hüttelová
- IVF Cube, IVF Laboratory , Prague, Czech Republic
| | - P Larsson
- Ferring Pharmaceuticals, Global Biometrics , Copenhagen, Denmark
| | | | - H Višnová
- IVF Cube, Reproductive Medicine , Prague, Czech Republic
| | - B Mannaerts
- Ferring Pharmaceuticals, Reproductive Medicine & Maternal Health , Copenhagen, Denmark
| |
Collapse
|
23
|
Ruiz M, González S, Bonnet C, Deng SX. Extracellular miR-6723-5p could serve as a biomarker of limbal epithelial stem/progenitor cell population. Biomark Res 2022; 10:36. [PMID: 35642012 PMCID: PMC9153202 DOI: 10.1186/s40364-022-00384-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Accepted: 05/16/2022] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Dysfunction or loss of limbal stem cells can result in limbal stem cell deficiency (LSCD), a disease that cause corneal opacity, pain, and loss of vision. Cultivated limbal epithelial transplantation (CLET) can be used to restore stem cell niche homeostasis and replenish the progenitor pool. Transplantation has been reported with high success rate, but there is an unmet need of prognostic markers that correlate with clinical outcomes. To date, the progenitor content in the graft is the only parameter that has been retrospectively linked to success. METHODS In this study, we investigate extracellular micro RNAs (miRNAs) associated with stem/progenitor cells in cultivated limbal epithelial cells (cLECs). Using micro RNA sequencing and linear regression modelling, we identify a miRNA signature in cultures containing high proportion of stem/progenitor cells. We then develop a robust RNA extraction workflow from culture media to confirm a positive miRNA correlation with stem/progenitor cell proportion. RESULTS miR-6723-5p is associated with cultures containing high proportion of stem/progenitor cells, and is detected in the basal layer of corneal epithelium. CONCLUSIONS These results indicate that miR-6723-5p could potentially serve as a stem/progenitor cell marker in cLECs.
Collapse
Affiliation(s)
- M. Ruiz
- Cornea Division, Stein Eye Institute, University of California, 100 Stein Plaza, Los Angeles, CA 90095 USA
| | - S. González
- Cornea Division, Stein Eye Institute, University of California, 100 Stein Plaza, Los Angeles, CA 90095 USA
| | - C. Bonnet
- Cornea Division, Stein Eye Institute, University of California, 100 Stein Plaza, Los Angeles, CA 90095 USA
- Cornea Department, Paris University, Cochin Hospital, AP-HP, F-75014 Paris, France
| | - S. X. Deng
- Cornea Division, Stein Eye Institute, University of California, 100 Stein Plaza, Los Angeles, CA 90095 USA
| |
Collapse
|
24
|
Ruiz M, Martín AM, Font C, Castellón V, Salgado M, Martínez E, Rupérez A, Cárdenas A, Martin-Lozano R, González-Caraballo I, Jiménez R, Morán LO, Salas E, Soria JM. OC-01: Mortality impact of cancer-associated venous thromboembolism: final analysis from Oncothromb12-01 study. Thromb Res 2022. [DOI: 10.1016/s0049-3848(22)00173-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Díaz J, DeFelipe I, Ruiz M, Andrés J, Ayarza P, Carbonell R. Identification of natural and anthropogenic signals in controlled source seismic experiments. Sci Rep 2022; 12:3171. [PMID: 35210484 PMCID: PMC8873501 DOI: 10.1038/s41598-022-07028-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Accepted: 02/10/2022] [Indexed: 11/09/2022] Open
Abstract
The analysis of the background noise in seismic networks has proved to be a powerful tool not only to acquire new insights on the crustal structure, but also to monitor different natural and anthropogenic processes. We show that data acquired during controlled source experiments can also be a valuable tool to monitor such processes, in particular when using high-density deployments. Data from a wide-angle reflection and refraction seismic profile in the central-northwest part of Iberia is used to identify signals related to aircrafts, road traffic, quarry blasts, wind blow, rainfall or thunders. The most prominent observations are those generated by a helicopter and an airplane flying following trajectories subparallel to the profile, which are tracked along 200 km with a spatial resolution of 350 m, hence providing an exceptional dataset. Other highlights are the observation of the Doppler effect on signals generated by moving cars and the high-density recording of acoustic waves generated by thunders. In addition to the intrinsic interest of identifying such signals, this contribution proves that it is worth inspecting the data acquired during seismic experiments beyond the time interval including the arrival of the seismic waves generated by the controlled source.
Collapse
Affiliation(s)
- J Díaz
- Geosciences Barcelona, Geo3Bcn CSIC, c/ Solé Sabarís s/n, 08028, Barcelona, Spain.
| | - I DeFelipe
- Department of Geology, Universidad de Salamanca, Plaza de la Merced, s/n, 37008, Salamanca, Spain
| | - M Ruiz
- Geosciences Barcelona, Geo3Bcn CSIC, c/ Solé Sabarís s/n, 08028, Barcelona, Spain
| | - J Andrés
- Geosciences Barcelona, Geo3Bcn CSIC, c/ Solé Sabarís s/n, 08028, Barcelona, Spain.,Institut Cartogràfic i Geològic de Catalunya, c/ Parc Montjuic s/n, 08038, Barcelona, Spain
| | - P Ayarza
- Department of Geology, Universidad de Salamanca, Plaza de la Merced, s/n, 37008, Salamanca, Spain
| | - R Carbonell
- Geosciences Barcelona, Geo3Bcn CSIC, c/ Solé Sabarís s/n, 08028, Barcelona, Spain
| |
Collapse
|
26
|
Repáraz D, Ruiz M, Llopiz D, Silva L, Vercher E, Aparicio B, Egea J, Tamayo-Uria I, Hervás-Stubbs S, García-Balduz J, Castro C, Iñarrairaegui M, Tagliamonte M, Mauriello A, Cavalluzzo B, Buonaguro L, Rohrer C, Heim K, Tauber C, Hofmann M, Thimme R, Sangro B, Sarobe P. Neoantigens as potential vaccines in hepatocellular carcinoma. J Immunother Cancer 2022; 10:jitc-2021-003978. [PMID: 35193931 PMCID: PMC9066373 DOI: 10.1136/jitc-2021-003978] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/26/2022] [Indexed: 12/21/2022] Open
Abstract
Background Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. Hepatocellular carcinoma (HCC) is a moderately mutated tumor, where the neoantigen repertoire has not been investigated. Our aim was to analyze whether tumors in HCC patients contain immunogenic neoantigens suitable for future use in therapeutic vaccination. Methods Whole-exome sequencing and RNAseq were performed in a cohort of fourteen HCC patients submitted to surgery or liver transplant. To identify mutations, single-nucleotide variants (SNV) originating non-synonymous changes that were confirmed at the RNA level were analyzed. Immunogenicity of putative neoAgs predicted by HLA binding algorithms was confirmed by using in vitro HLA binding assays and T-cell stimulation experiments, the latter in vivo, by immunizing HLA-A*02.01/HLA-DRB1*01 (HHD-DR1) transgenic mice, and in in vitro, using human lymphocytes. Results Sequencing led to the identification of a median of 1217 missense somatic SNV per patient, narrowed to 30 when filtering by using RNAseq data. A median of 13 and 5 peptides per patient were predicted as potential binders to HLA class I and class II molecules, respectively. Considering only HLA-A*02.01- and HLA-DRB1*01-predicted binders, 70% demonstrated HLA-binding capacity and about 50% were immunogenic when tested in HHD-DR1 mice. These peptides induced polyfunctional T cells that specifically recognized the mutated but not the wild-type sequence as well as neoantigen-expressing cells. Moreover, coimmunization experiments combining CD8 and CD4 neoantigen epitopes resulted in stronger CD8 T cell responses. Finally, responses against neoantigens were also induced in vitro using human cells. Conclusion These results show that mutations in HCC tumors may generate immunogenic neoantigens with potential applicability for future combinatorial therapeutic strategies.
Collapse
Affiliation(s)
- David Repáraz
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Marta Ruiz
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Diana Llopiz
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Leyre Silva
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Enric Vercher
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Belén Aparicio
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Josune Egea
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Ibon Tamayo-Uria
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Sandra Hervás-Stubbs
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Jorge García-Balduz
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
| | - Carla Castro
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain
| | - Mercedes Iñarrairaegui
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.,Liver Unit, Clínica Universidad de Navarra, Pamplona, Spain
| | - Maria Tagliamonte
- Innovative Immunological Models, Istituto Nazionale Tumori - IRCCS - "Fond G. Pascale", Napoli, Italy
| | - Angela Mauriello
- Innovative Immunological Models, Istituto Nazionale Tumori - IRCCS - "Fond G. Pascale", Napoli, Italy
| | - Beatrice Cavalluzzo
- Innovative Immunological Models, Istituto Nazionale Tumori - IRCCS - "Fond G. Pascale", Napoli, Italy
| | - Luigi Buonaguro
- Innovative Immunological Models, Istituto Nazionale Tumori - IRCCS - "Fond G. Pascale", Napoli, Italy
| | - Charlotte Rohrer
- Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Kathrin Heim
- Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.,Faculty of Biology, University of Freiburg, Freiburg, Germany
| | - Catrin Tauber
- Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Maike Hofmann
- Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Robert Thimme
- Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Bruno Sangro
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.,Liver Unit, Clínica Universidad de Navarra, Pamplona, Spain
| | - Pablo Sarobe
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain .,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| |
Collapse
|
27
|
Spina E, Doneddu PE, Liberatore G, Cocito D, Fazio R, Briani C, Filosto M, Benedetti L, Antonini G, Cosentino G, Jann S, Mazzeo A, Cortese A, Marfia GA, Clerici AM, Siciliano G, Carpo M, Luigetti M, Lauria G, Rosso T, Cavaletti G, Peci E, Tronci S, Ruiz M, Piccinelli SC, Schenone A, Leonardi L, Gentile L, Piccolo L, Mataluni G, Santoro L, Nobile-Orazio E, Manganelli F. The neurophysiological lesson from the Italian CIDP database. Neurol Sci 2022. [PMID: 34021439 DOI: 10.1007/s10072-020-04998-y.10.1007/s10072-020-04998-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
INTRODUCTION Electrophysiological diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) may be challenging. Thus, with the aim ofproviding some practical advice in electrophysiological approach to a patient with suspected CIDP, we analyzed electrophysiological data from 499 patients enrolled inthe Italian CIDP Database. METHODS We calculated the rate of each demyelinating feature, the rate of demyelinating features per nerve, the diagnostic rate for upper andlower limb nerves, and, using a ROC curve analysis, the diagnostic accuracy of each couple of nerves and each demyelinating feature, for every CIDP subtype.Moreover, we compared the electrophysiological data of definite and probable CIDP patients with those of possible and not-fulfilling CIDP patients, and by a logisticregression analysis, we estimated the odds ratio (OR) to make an electrophysiological diagnosis of definite or probable CIDP. RESULTS The ulnar nerve had the highestrate of demyelinating features and, when tested bilaterally, had the highest diagnostic accuracy except for DADS in which peroneal nerves were the most informative.In possible and not-fulfilling CIDP patients, a lower number of nerves and proximal temporal dispersion (TD) measurements had been performed compared to definiteand probable CIDP patients. Importantly, OR for each tested motor nerve and each TD measurement was 1.59 and 1.33, respectively. CONCLUSION Our findingsdemonstrated that the diagnosis of CIDP may be missed due to inadequate or incomplete electrophysiological examination or interpretation. At the same time, thesedata taken together could be useful to draw a thoughtful electrophysiological approach to patients suspected of CIDP.
Collapse
Affiliation(s)
- Emanuele Spina
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Via Pansini, 5, 81025, Naples, Italy.
| | - Pietro Emiliano Doneddu
- Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy
| | - Giuseppe Liberatore
- Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy
| | - Dario Cocito
- Presidio Sanitario Major, Istituti Clinici Scientifici Maugeri, Turin, Italy
| | - Raffaella Fazio
- Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy
| | - Chiara Briani
- Neurology Unit, Department of Neuroscience, University of Padova, Padova, Italy
| | - Massimiliano Filosto
- Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy
| | - Luana Benedetti
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS San Martino, Genoa, Italy
- IRCCS AOU San Martino-IST, Genoa, Italy
| | - Giovanni Antonini
- Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Sant'Andrea Hospital, Rome, Italy
| | - Giuseppe Cosentino
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
- IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy
| | - Stefano Jann
- Department of Neuroscience, Niguarda Ca' Granda Hospital, Milan, Italy
| | - Anna Mazzeo
- Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy
| | - Andrea Cortese
- IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy
- Molecular Neurosciences, University College London, London, UK
| | - Girolama Alessandra Marfia
- Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy
| | - Angelo Maurizio Clerici
- Neurology Unit, Circolo & Macchi Foundation Hospital, Insubria University, DBSV, Varese, Italy
| | - Gabriele Siciliano
- Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Marinella Carpo
- Neurology Unit, ASST Bergamo Ovest-Ospedale Treviglio, Treviglio, Italy
| | - Marco Luigetti
- Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Giuseppe Lauria
- Unit of Neuroalgology, IRCCS Foundation 'Carlo Besta' Neurological Institute, Milan, Italy
- Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Milan, Italy
| | - Tiziana Rosso
- ULSS2 Marca Trevigiana, UOC Neurologia-Castelfranco Veneto, Treviso, Italy
| | - Guido Cavaletti
- School of Medicine and Surgery and Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy
| | - Erdita Peci
- Presidio Sanitario Major, Istituti Clinici Scientifici Maugeri, Turin, Italy
| | - Stefano Tronci
- Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy
| | - Marta Ruiz
- Neurology Unit, Department of Neuroscience, University of Padova, Padova, Italy
| | - Stefano Cotti Piccinelli
- Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy
| | - Angelo Schenone
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS San Martino, Genoa, Italy
| | - Luca Leonardi
- Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Sant'Andrea Hospital, Rome, Italy
| | - Luca Gentile
- Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy
| | - Laura Piccolo
- IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy
| | - Giorgia Mataluni
- Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy
| | - Lucio Santoro
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Via Pansini, 5, 81025, Naples, Italy
| | - Eduardo Nobile-Orazio
- Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy
- Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy
| | - Fiore Manganelli
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Via Pansini, 5, 81025, Naples, Italy.
| |
Collapse
|
28
|
Aparicio B, Ruiz M, Casares N, Silva L, Egea J, Pérez P, Albericio G, Esteban M, García-Arriaza J, Lasarte JJ, Sarobe P. Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies. Front Immunol 2022; 13:1044025. [PMID: 36761163 PMCID: PMC9902865 DOI: 10.3389/fimmu.2022.1044025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 12/29/2022] [Indexed: 01/26/2023] Open
Abstract
Current vaccines against SARS-CoV-2, based on the original Wuhan sequence, induce antibodies with different degrees of cross-recognition of new viral variants of concern. Despite potent responses generated in vaccinated and infected individuals, the Omicron (B.1.1.529) variant causes breakthrough infections, facilitating viral transmission. We previously reported a vaccine based on a cyclic peptide containing the 446-488 S1 sequence (446-488cc) of the SARS-CoV-2 spike (S) protein from Wuhan isolate. To provide the best immunity against Omicron, here we compared Omicron-specific immunity induced by a Wuhan-based 446-488cc peptide, by a Wuhan-based recombinant receptor-binding domain (RBD) vaccine and by a new 446-488cc peptide vaccine based on the Omicron sequence. Antibodies induced by Wuhan peptide 446-488cc in three murine strains not only recognized the Wuhan and Omicron 446-488 peptides similarly, but also Wuhan and Omicron RBD protein variants. By contrast, antibodies induced by the Wuhan recombinant RBD vaccine showed a much poorer cross-reactivity for the Omicron RBD despite similar recognition of Wuhan and Omicron peptide variants. Finally, although the Omicron-based 446-488cc peptide vaccine was poorly immunogenic in mice due to the loss of T cell epitopes, co-immunization with Omicron peptide 446-488cc and exogenous T cell epitopes induced strong cross-reactive antibodies that neutralized Omicron SARS-CoV-2 virus. Since mutations occurring within this sequence do not alter T cell epitopes in humans, these results indicate the robust immunogenicity of 446-488cc-based peptide vaccines that induce antibodies with a high cross-recognition capacity against Omicron, and suggest that this sequence could be included in future vaccines targeting the Omicron variant.
Collapse
Affiliation(s)
- Belén Aparicio
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Marta Ruiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Noelia Casares
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Leyre Silva
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Josune Egea
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Patricia Pérez
- Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain
| | - Guillermo Albericio
- Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Mariano Esteban
- Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Juan García-Arriaza
- Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain
| | - Juan J Lasarte
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Pablo Sarobe
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| |
Collapse
|
29
|
De Moraes Prata Gaspar MC, Ruiz M, Puiggròs C. “¿Cuánto le dura la vida?”: análisis cualitativo de los conocimientos, percepciones y usos de los alimentos fermentados entre personas jóvenes adultas residentes en la ciudad de Barcelona. Rev Esp Nutr Hum Diet 2021. [DOI: 10.14306/renhyd.25.4.1313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Introducción: Las percepciones de los alimentos varían histórica y socioculturalmente. Los alimentos fermentados han formado parte de las dietas desde la Antigüedad y, en España, hay una amplia diversidad de alimentos fermentados. Si en la literatura científica abundan los conocimientos sobre estos alimentos desde el punto de vista histórico, tecnológico y nutricional, existe una escasez de estudios sobre las percepciones y usos de los productos fermentados. Desde la perspectiva de la antropología de la alimentación, este estudio buscó identificar los conocimientos, percepciones y usos que se tienen y practican con alimentos fermentados.
Material y métodos: Se realizó un estudio cualitativo transversal y exploratorio a partir de tres grupos de discusión con personas jóvenes adultas de la ciudad de Barcelona, dinamizados a través de un guion con 24 preguntas. Se transcribieron los discursos y se realizó un análisis temático.
Resultados: La categoría “alimento fermentado” es polisémica. En general, el proceso de fermentación era desconocido o explicado con cierta dificultad. Los individuos percibían los productos fermentados y sus procesos de elaboración desde múltiples dimensiones expresadas a partir de valores dicotómicos que se entrecruzan: agradables y desagradables al gusto, tradicionales y novedosos, conveniente e inconveniente para la salud, industrial y artesanal/casero, confianza/seguridad y desconfianza/riesgo. Se observó una baja presencia de estos alimentos en las dietas declaradas.
Conclusiones: Se usaron diferentes racionalidades para definir los productos fermentados: según el proceso de fermentación, las prácticas culinarias, el alimento y su composición y según los usos, las maneras en la mesa y el lugar que ocupa en cada cultura alimentaria. Aunque la relación entre estos alimentos y sus efectos en la salud ocuparon un lugar destacado en los discursos, los criterios de consumo variaban según cada alimento fermentado e informante y, en general, el consumo no se debía a su condición de fermentado.
Collapse
|
30
|
Aparicio B, Casares N, Egea J, Ruiz M, Llopiz D, Maestro S, Olagüe C, González-Aseguinolaza G, Smerdou C, López-Díaz de Cerio A, Inogés S, Prósper F, Yuste JR, Carmona-Torre F, Reina G, Lasarte JJ, Sarobe P. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Emerg Microbes Infect 2021; 10:1931-1946. [PMID: 34538222 PMCID: PMC8480813 DOI: 10.1080/22221751.2021.1978823] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Abstract
Identification of relevant epitopes is crucial for the development of subunit peptide vaccines inducing neutralizing and cellular immunity against SARS-CoV-2. Our aim was the characterization of epitopes in the receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein to generate a peptide vaccine. Epitope mapping using a panel of 10 amino acid overlapped 15-mer peptides covering region 401-515 from RBD did not identify linear epitopes when tested with sera from infected individuals or from RBD-immunized mice. However, immunization of mice with these 15-mer peptides identified four peptides located at region 446-480 that induced antibodies recognizing the peptides and RBD/S1 proteins. Immunization with peptide 446-480 from S protein formulated with Freund's adjuvant or with CpG oligodeoxinucleotide/Alum induced polyepitopic antibody responses in BALB/c and C56BL/6J mice, recognizing RBD (titres of 3 × 104-3 × 105, depending on the adjuvant) and displaying neutralizing capacity (80-95% inhibition capacity; p < 0.05) against SARS-CoV-2. Murine CD4 and CD8T-cell epitopes were identified in region 446-480 and vaccination experiments using HLA transgenic mice suggested the presence of multiple human T-cell epitopes. Antibodies induced by peptide 446-480 showed broad recognition of S proteins and S-derived peptides belonging to SARS-CoV-2 variants of concern. Importantly, vaccination with peptide 446-480 or with a cyclic version of peptide 446-488 containing a disulphide bridge between cysteines 480 and 488, protected humanized K18-hACE2 mice from a lethal dose of SARS-CoV-2 (62.5 and 75% of protection; p < 0.01 and p < 0.001, respectively). This region could be the basis for a peptide vaccine or other vaccine platforms against Covid-19.
Collapse
Affiliation(s)
- Belén Aparicio
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Noelia Casares
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Josune Egea
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Marta Ruiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Diana Llopiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Sheila Maestro
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Cristina Olagüe
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Gloria González-Aseguinolaza
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Cristian Smerdou
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | | | | | - Felipe Prósper
- Clínica Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain
| | | | | | | | - Juan J Lasarte
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Pablo Sarobe
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.,IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| |
Collapse
|
31
|
Ruiz M, Puthenparampil M, Campagnolo M, Castellani F, Salvalaggio A, Ruggero S, Toffanin E, Cacciavillani M, Gallo P, Franciotta D, Briani C. Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies. J Neurol Neurosurg Psychiatry 2021; 92:969-974. [PMID: 33850000 DOI: 10.1136/jnnp-2020-325868] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 03/20/2021] [Accepted: 03/22/2021] [Indexed: 12/13/2022]
Abstract
BACKGROUND Cerebrospinal fluid (CSF) albumincytologic dissociation represents a supportive diagnostic criterion of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).Few studies have investigated possible systemic or intrathecal humoral immune response activation in CIDP.Aim of our study was to investigate whether the search of oligoclonal IgG bands (OCBs) might provide additional data helpful in CIDP diagnostic work-up. METHODS Forty-eight consecutive patients with CIDP (34 men, mean age 59.4, range 16-83) were recruited. CSF analysis included nephelometric measurement of albumin and IgG concentrations, calculation of QALB, QAlbLIM and intrathecal IgG synthesis, and OCBs detection with isoelectric focusing. Data were compared with those from CSF and serum of 32 patients with Guillain-Barré syndrome (GBS), 18 patients with anti-myelin associated glycoprotein (MAG) antibody neuropathy, 4 patients with multifocal motor neuropathy and 32 patients with non-inflammatory neuropathies (NINPs). RESULTS Patients with CIDP and anti-MAG antibody neuropathy had significantly higher CSF albumin concentrations and QALB values than NINPs (p=0.0003 and p=0.0095, respectively). A total of 9 (19%) patients with CIDP presented identical serum and CSF OCBs ('mirror pattern') versus 3 patients (16.6%) with anti-MAG antibody neuropathy, 13 patients (40.6%) with GBS and 12.5% patients with NINPs. Only one patient with CIDP showed unique-to-CSF OCBs. First-line therapy was effective in 80.4% of patients with CIDP, irrespective of CSF findings. CONCLUSIONS Compared with NINP, CIDP, GBS and anti-MAG antibody neuropathies had a significantly increased CSF protein and blood-spinal nerve root barrier damage. Intrathecal humoral immune response is rare in our patients with CIDP. Systemic oligoclonal activation is more frequent, but not significantly different from what was detected in the control groups.
Collapse
Affiliation(s)
- Marta Ruiz
- Department of Neurosciences (DNS), University of Padova, Padova, Italy
| | | | - Marta Campagnolo
- Department of Neurosciences (DNS), University of Padova, Padova, Italy
| | | | - Alessandro Salvalaggio
- Department of Neurosciences (DNS), University of Padova, Padova, Italy.,Padova Neuroscience Center (PNC), Padova, Italy
| | - Susanna Ruggero
- Department of Neurosciences (DNS), University of Padova, Padova, Italy
| | | | | | - Paolo Gallo
- Department of Neurosciences (DNS), University of Padova, Padova, Italy
| | | | - Chiara Briani
- Department of Neurosciences (DNS), University of Padova, Padova, Italy
| |
Collapse
|
32
|
Ruiz M, Acosta DB, Baricalla A, Sánchez JP. Molecular detection of Rickettsia in ectoparasites (Siphonaptera and Phthiraptera) of domestic and feral pigs from Argentina. Parasitol Res 2021; 120:3611-3618. [PMID: 34435254 DOI: 10.1007/s00436-021-07291-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Accepted: 08/10/2021] [Indexed: 10/20/2022]
Abstract
Rickettsioses are distributed among a variety of hematophagous arthropods, and represent an emergent threat. The presence of rickettsial bacteria in ectoparasites collected from pigs from Argentina is still unknown. This study investigated the presence and identity of Rickettsia spp. in fleas, Pulex irritans, and sucking lice, Haematopinus suis, of domestic and feral pigs, Sus scrofa, from Central-Northern Argentina, through the genes gltA and ompB. Rickettsial bacteria were detected in 50% of fleas and 24% of lice. The BLASTn analysis of the ompB gene fragments in P. irritans samples showed identities 99% and 100% with R. felis. Positive samples of H. suis were 99% similar with species from the spotted fever group, future amplifications of a more polymorphic fragment of the ompB gene will allow to corroborate the identity of the Rickettsia species present in these lice samples. The Rickettsia spp. reported in the present study are having eventually been associated with cases of human diseases, and the circulation of these agents in arthropods has already been reported in several countries. Therefore, the identification of circulating pathogenic agents, such as reported in this study, is crucial for development of preventive measures for the control of ectoparasite-borne rickettsiosis diseases. Further studies, using serology techniques, will be allow to explore the ability of pigs as a possible Rickettsia reservoir and its role as part of transmission cycle of Rickettsia spp. in the studied scenarios.
Collapse
Affiliation(s)
- M Ruiz
- Centro de Bioinvestigaciones - CeBio, Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires-CIT NOBA (CONICET-UNNOBA-UNSAdA), Ruta Provincial 32 Km 3.5, 2700, Pergamino, Buenos Aires, Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - D B Acosta
- Centro de Bioinvestigaciones - CeBio, Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires-CIT NOBA (CONICET-UNNOBA-UNSAdA), Ruta Provincial 32 Km 3.5, 2700, Pergamino, Buenos Aires, Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - A Baricalla
- Centro de Bioinvestigaciones - CeBio, Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires-CIT NOBA (CONICET-UNNOBA-UNSAdA), Ruta Provincial 32 Km 3.5, 2700, Pergamino, Buenos Aires, Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - J P Sánchez
- Centro de Bioinvestigaciones - CeBio, Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires-CIT NOBA (CONICET-UNNOBA-UNSAdA), Ruta Provincial 32 Km 3.5, 2700, Pergamino, Buenos Aires, Argentina. .,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
| |
Collapse
|
33
|
García-Azorín D, Sierra Á, Trigo J, Alberdi A, Blanco M, Calcerrada I, Cornejo A, Cubero M, Gil A, García-Iglesias C, Lozano AG, Martínez Badillo C, Montilla C, Mora M, Núñez G, Paniagua M, Pérez C, Rojas M, Ruiz M, Sierra L, Hurtado ML, Guerrero Peral ÁL. Frequency and phenotype of headache in covid-19: a study of 2194 patients. Sci Rep 2021; 11:14674. [PMID: 34282206 PMCID: PMC8290038 DOI: 10.1038/s41598-021-94220-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Accepted: 07/05/2021] [Indexed: 01/08/2023] Open
Abstract
To estimate the frequency of headache in patients with confirmed COVID-19 and characterize the phenotype of headache attributed to COVID-19, comparing patients depending on the need of hospitalization and sex, an observational study was done. We systematically screened all eligible patients from a reference population of 261,431 between March 8 (first case) and April 11, 2020. A physician administered a survey assessing demographic and clinical data and the phenotype of the headache. During the study period, 2194 patients out of the population at risk were diagnosed with COVID-19. Headache was described by 514/2194 patients (23.4%, 95% CI 21.7–25.3%), including 383/1614 (23.7%) outpatients and 131/580 (22.6%) inpatients. The headache phenotype was studied in detail in 458 patients (mean age, 51 years; 72% female; prior history of headache, 49%). Headache was the most frequent first symptom of COVID-19. Median headache onset was within 24 h, median duration was 7 days and persisted after 1 month in 13% of patients. Pain was bilateral (80%), predominantly frontal (71%), with pressing quality (75%), of severe intensity. Systemic symptoms were present in 98% of patients. Headache frequency and phenotype was similar in patients with and without need for hospitalization and when comparing male and female patients, being more intense in females. Trial registration: This study was supported by the Institute of Health Carlos III (ISCIII), code 07.04.467804.74011 and Regional Health Administration, Gerencia Regional de Salud, Castilla y Leon (GRS: 2289/A/2020).
Collapse
Affiliation(s)
- David García-Azorín
- Headache Unit, Department of Neurology, Hospital Clínico Universitario de Valladolid, Avenida Ramón y Cajal N° 3, 47003, Valladolid, Spain.
| | - Álvaro Sierra
- Headache Unit, Department of Neurology, Hospital Clínico Universitario de Valladolid, Avenida Ramón y Cajal N° 3, 47003, Valladolid, Spain
| | - Javier Trigo
- Headache Unit, Department of Neurology, Hospital Clínico Universitario de Valladolid, Avenida Ramón y Cajal N° 3, 47003, Valladolid, Spain
| | - Ana Alberdi
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | - María Blanco
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | | | - Ana Cornejo
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | - Miguel Cubero
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | - Ana Gil
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | | | | | | | - Carol Montilla
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | - Marta Mora
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | - Gabriela Núñez
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | - Marina Paniagua
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | - Carolina Pérez
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | - María Rojas
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | - Marta Ruiz
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | - Leticia Sierra
- Valladolid East Primary Care Basic Health Area, Valladolid, Spain
| | | | - Ángel Luis Guerrero Peral
- Headache Unit, Department of Neurology, Hospital Clínico Universitario de Valladolid, Avenida Ramón y Cajal N° 3, 47003, Valladolid, Spain.,Department of Medicine and toxicology, University of Valladolid, Valladolid, Spain
| |
Collapse
|
34
|
Mosquera-Klinger G, Berrio S, Carvajal JJ, Juliao-Baños F, Ruiz M. Ulcerative proctitis associated with lymphogranuloma venereum. Rev Gastroenterol Mex (Engl Ed) 2021; 86:313-315. [PMID: 34154973 DOI: 10.1016/j.rgmxen.2021.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 06/24/2020] [Indexed: 11/26/2022]
Affiliation(s)
- G Mosquera-Klinger
- Unidad de Gastroenterología y Endoscopia Digestiva, Hospital Pablo Tobón Uribe, Medellín, Colombia.
| | - S Berrio
- Unidad de Gastroenterología y Endoscopia Digestiva, Hospital Pablo Tobón Uribe, Medellín, Colombia
| | - J J Carvajal
- Unidad de Gastroenterología y Endoscopia Digestiva, Hospital Pablo Tobón Uribe, Medellín, Colombia
| | - F Juliao-Baños
- Unidad de Gastroenterología y Endoscopia Digestiva, Hospital Pablo Tobón Uribe, Medellín, Colombia
| | - M Ruiz
- Unidad de Gastroenterología y Endoscopia Digestiva, Hospital Pablo Tobón Uribe, Medellín, Colombia
| |
Collapse
|
35
|
Spina E, Doneddu PE, Liberatore G, Cocito D, Fazio R, Briani C, Filosto M, Benedetti L, Antonini G, Cosentino G, Jann S, Mazzeo A, Cortese A, Marfia GA, Clerici AM, Siciliano G, Carpo M, Luigetti M, Lauria G, Rosso T, Cavaletti G, Peci E, Tronci S, Ruiz M, Piccinelli SC, Schenone A, Leonardi L, Gentile L, Piccolo L, Mataluni G, Santoro L, Nobile-Orazio E, Manganelli F. Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP. J Neurol 2021; 269:907-912. [PMID: 34173874 PMCID: PMC8782796 DOI: 10.1007/s00415-021-10672-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Revised: 06/14/2021] [Accepted: 06/14/2021] [Indexed: 12/22/2022]
Abstract
Compression of the median nerve at the carpal tunnel can give demyelinating features and result in distal motor latency (DML) prolongation fulfilling the EFNS/PNS demyelinating criteria for chronic inflammatory demyelinating polyneuropathy (CIDP). Accordingly, being carpal tunnel syndrome (CTS) common in the general population, the EFNS/PNS guidelines recommend excluding the DML of the median nerve when DML prolongation may be consistent with median neuropathy at the wrist from CTS. The main aims of this study were to verify whether the inclusion of DML of the median nerve (when consistent with CTS) could improve electrophysiological diagnostic accuracy for CIDP and if the median nerve at the carpal tunnel was more prone to demyelination. We analyzed electrophysiological data from 499 patients included consecutively into the Italian CIDP Database. According to the EFNS/PNS criteria, 352 patients had a definite, 10 a probable, and 57 a possible diagnosis of CIDP, while 80 were not fulfilling the diagnostic criteria. The inclusion of DML prolongation of median nerve did not improve significantly the diagnostic accuracy for CIDP; overall diagnostic class changed in 6 out of 499 patients (1.2%) and electrodiagnostic class of CIDP changed from not fulfilling to possible in only 2 patients (2.5% of not-fulfilling patients). In conclusion, we can infer that excluding DML prolongation of median nerve does not increase the risk of missing a diagnosis of CIDP thus corroborating the current EFNS/PNS criteria.
Collapse
Affiliation(s)
- Emanuele Spina
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Via Pansini, 5, 81025, Naples, Italy.
| | - Pietro Emiliano Doneddu
- Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Clinical and Research Institute, Rozzano, Milan, Italy
| | - Giuseppe Liberatore
- Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Clinical and Research Institute, Rozzano, Milan, Italy
| | - Dario Cocito
- Presidio Sanitario Major, Istituti Clinici Scientifici Maugeri, Turin, Italy
| | - Raffaella Fazio
- Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy
| | - Chiara Briani
- Department of Neuroscience, Neurology Unit, University of Padova, Padova, Italy
| | - Massimiliano Filosto
- Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy
| | - Luana Benedetti
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS San Martino, Genoa, Italy
- IRCCS AOU San Martino-IST, Genoa, Italy
| | - Giovanni Antonini
- Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sant'Andrea Hospital, 'Sapienza' University of Rome, Rome, Italy
| | - Giuseppe Cosentino
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
- IRCCS Mondino Foundation, Pavia, Italy
| | - Stefano Jann
- Department of Neuroscience, Niguarda Ca' Granda Hospital, Milan, Italy
| | - Anna Mazzeo
- Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy
| | - Andrea Cortese
- IRCCS Mondino Foundation, Pavia, Italy
- Molecular Neurosciences, University College London, London, UK
| | - Girolama Alessandra Marfia
- Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy
| | - Angelo Maurizio Clerici
- Neurology Unit, Circolo and Macchi Foundation Hospital, Insubria University, DBSV, Varese, Italy
| | - Gabriele Siciliano
- Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Marinella Carpo
- Neurology Unit, ASST Bergamo Ovest-Ospedale Treviglio, Treviglio, Italy
| | - Marco Luigetti
- UOC Neurologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Giuseppe Lauria
- Unit of Neuroalgology, IRCCS Foundation 'Carlo Besta' Neurological Institute, Milan, Italy
- Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Milan, Italy
| | - Tiziana Rosso
- ULSS2 Marca Trevigiana, UOC Neurologia-Castelfranco Veneto, Treviso, Italy
| | - Guido Cavaletti
- School of Medicine and Surgery and Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy
| | - Erdita Peci
- Presidio Sanitario Major, Istituti Clinici Scientifici Maugeri, Turin, Italy
| | - Stefano Tronci
- Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy
| | - Marta Ruiz
- Department of Neuroscience, Neurology Unit, University of Padova, Padova, Italy
| | - Stefano Cotti Piccinelli
- Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy
| | - Angelo Schenone
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS San Martino, Genoa, Italy
| | - Luca Leonardi
- Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sant'Andrea Hospital, 'Sapienza' University of Rome, Rome, Italy
| | - Luca Gentile
- Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy
| | | | - Giorgia Mataluni
- Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy
| | - Lucio Santoro
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Via Pansini, 5, 81025, Naples, Italy
| | - Eduardo Nobile-Orazio
- Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Clinical and Research Institute, Rozzano, Milan, Italy
- Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy
| | - Fiore Manganelli
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Via Pansini, 5, 81025, Naples, Italy
| |
Collapse
|
36
|
Spina E, Doneddu PE, Liberatore G, Cocito D, Fazio R, Briani C, Filosto M, Benedetti L, Antonini G, Cosentino G, Jann S, Mazzeo A, Cortese A, Marfia GA, Clerici AM, Siciliano G, Carpo M, Luigetti M, Lauria G, Rosso T, Cavaletti G, Peci E, Tronci S, Ruiz M, Piccinelli SC, Schenone A, Leonardi L, Gentile L, Piccolo L, Mataluni G, Santoro L, Nobile-Orazio E, Manganelli F. The neurophysiological lesson from the Italian CIDP database. Neurol Sci 2021; 43:573-582. [PMID: 34021439 PMCID: PMC8724146 DOI: 10.1007/s10072-021-05321-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Accepted: 05/14/2021] [Indexed: 12/22/2022]
Abstract
Introduction Electrophysiological diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) may be challenging. Thus, with the aim ofproviding some practical advice in electrophysiological approach to a patient with suspected CIDP, we analyzed electrophysiological data from 499 patients enrolled inthe Italian CIDP Database. Methods We calculated the rate of each demyelinating feature, the rate of demyelinating features per nerve, the diagnostic rate for upper andlower limb nerves, and, using a ROC curve analysis, the diagnostic accuracy of each couple of nerves and each demyelinating feature, for every CIDP subtype.Moreover, we compared the electrophysiological data of definite and probable CIDP patients with those of possible and not-fulfilling CIDP patients, and by a logisticregression analysis, we estimated the odds ratio (OR) to make an electrophysiological diagnosis of definite or probable CIDP. Results The ulnar nerve had the highestrate of demyelinating features and, when tested bilaterally, had the highest diagnostic accuracy except for DADS in which peroneal nerves were the most informative.In possible and not-fulfilling CIDP patients, a lower number of nerves and proximal temporal dispersion (TD) measurements had been performed compared to definiteand probable CIDP patients. Importantly, OR for each tested motor nerve and each TD measurement was 1.59 and 1.33, respectively. Conclusion Our findingsdemonstrated that the diagnosis of CIDP may be missed due to inadequate or incomplete electrophysiological examination or interpretation. At the same time, thesedata taken together could be useful to draw a thoughtful electrophysiological approach to patients suspected of CIDP. Supplementary Information The online version contains supplementary material available at 10.1007/s10072-021-05321-z.
Collapse
Affiliation(s)
- Emanuele Spina
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Via Pansini, 5, 81025, Naples, Italy.
| | - Pietro Emiliano Doneddu
- Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy
| | - Giuseppe Liberatore
- Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy
| | - Dario Cocito
- Presidio Sanitario Major, Istituti Clinici Scientifici Maugeri, Turin, Italy
| | - Raffaella Fazio
- Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy
| | - Chiara Briani
- Neurology Unit, Department of Neuroscience, University of Padova, Padova, Italy
| | - Massimiliano Filosto
- Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy
| | - Luana Benedetti
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS San Martino, Genoa, Italy
- IRCCS AOU San Martino-IST, Genoa, Italy
| | - Giovanni Antonini
- Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Sant'Andrea Hospital, Rome, Italy
| | - Giuseppe Cosentino
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
- IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy
| | - Stefano Jann
- Department of Neuroscience, Niguarda Ca' Granda Hospital, Milan, Italy
| | - Anna Mazzeo
- Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy
| | - Andrea Cortese
- IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy
- Molecular Neurosciences, University College London, London, UK
| | - Girolama Alessandra Marfia
- Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy
| | - Angelo Maurizio Clerici
- Neurology Unit, Circolo & Macchi Foundation Hospital, Insubria University, DBSV, Varese, Italy
| | - Gabriele Siciliano
- Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Marinella Carpo
- Neurology Unit, ASST Bergamo Ovest-Ospedale Treviglio, Treviglio, Italy
| | - Marco Luigetti
- Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Giuseppe Lauria
- Unit of Neuroalgology, IRCCS Foundation 'Carlo Besta' Neurological Institute, Milan, Italy
- Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Milan, Italy
| | - Tiziana Rosso
- ULSS2 Marca Trevigiana, UOC Neurologia-Castelfranco Veneto, Treviso, Italy
| | - Guido Cavaletti
- School of Medicine and Surgery and Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy
| | - Erdita Peci
- Presidio Sanitario Major, Istituti Clinici Scientifici Maugeri, Turin, Italy
| | - Stefano Tronci
- Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy
| | - Marta Ruiz
- Neurology Unit, Department of Neuroscience, University of Padova, Padova, Italy
| | - Stefano Cotti Piccinelli
- Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy
| | - Angelo Schenone
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS San Martino, Genoa, Italy
| | - Luca Leonardi
- Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Sant'Andrea Hospital, Rome, Italy
| | - Luca Gentile
- Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy
| | - Laura Piccolo
- IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy
| | - Giorgia Mataluni
- Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy
| | - Lucio Santoro
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Via Pansini, 5, 81025, Naples, Italy
| | - Eduardo Nobile-Orazio
- Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy
- Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy
| | - Fiore Manganelli
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Via Pansini, 5, 81025, Naples, Italy.
| |
Collapse
|
37
|
Burelle C, Deschênes S, Cuillerier A, De Loof M, Daneault C, Burelle Y, Ruiz M. Evidence for a cardiometabolic sexual dimorphism in a non-obese mouse model of hepatic Lrpprc deficiency exhibiting microvesicular steatosis. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2021.04.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Torres-Ferrus M, López-Veloso AC, Gonzalez-Quintanilla V, González-García N, Díaz de Teran J, Gago-Veiga A, Camiña J, Ruiz M, Mas-Sala N, Bohórquez S, Gallardo VJ, Pozo-Rosich P. The MIGREX study: Prevalence and risk factors of sexual dysfunction among migraine patients. Neurologia 2021; 38:S0213-4853(21)00036-0. [PMID: 33766414 DOI: 10.1016/j.nrl.2021.02.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Revised: 01/04/2021] [Accepted: 02/07/2021] [Indexed: 10/21/2022] Open
Abstract
BACKGROUND Migraine attacks have a high impact on daily activities. There is limited research on the burden of migraine on sexual functioning. OBJECTIVE To determine the prevalence of sexual dysfunction in patients with migraine and its relationship with migraine features and comorbidities. METHOD This is a cross-sectional study. We included migraine patients between 18 and 60 years-old from 8 Headache Clinics in Spain. We recorded demographic data and migraine features. Patients fulfilled a survey including comorbidities, Arizona Sexual Experiences Scale, Hospital Anxiety and Depression Scale and a questionnaire about migraine impact on sexual activity. A K-nearest neighbor supervised learning algorithm was used to identify differences between migraine patients with and without sexual dysfunction. RESULTS We included 306 patients (85.6% women, mean age 42.3±11.1 years). A 41.8% of participants had sexual dysfunction. Sexual dysfunction was associated with being female (OR [95% CI]: 2.42 [1.17-5.00]; p<0.001), being older than 46.5 years (4.04 [2.48-6.59]; p<0.001), having chronic migraine (2.31 [1.41-3.77]; p=0.001), using preventive medication (2.45 [1.35-4.45]; p=0.004), analgesic overusing (3.51 [2.03-6.07]; p<0.001), menopause (4.18 [2.43-7.17]; p<0.001) and anxiety (2.90 [1.80-4.67]; p<0.001) and depression (6.14 [3.18-11.83]; p<0.001). However, only female gender, age, menopause and depression were the statistically significant variables selected in the model to classify migraine patients with or without sexual dysfunction (Accuracy [95% CI]: 0.75 (0.62-0.85), Kappa: 0.48, p=0.005). CONCLUSIONS Sexual dysfunction is frequent in migraine patients visited in a headache clinic. However, migraine characteristics or use of preventive medication are not directly associated with sexual dysfunction. Instead, risk factors for sexual dysfunction were female gender, higher age, menopause and depression.
Collapse
Affiliation(s)
- M Torres-Ferrus
- Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
| | - A C López-Veloso
- Neurology Department, Gran Canaria Dr. Negrín University Hospital, Las Palmas de Gran Canaria, Spain
| | | | | | - J Díaz de Teran
- Neurology Department, La Paz University Hospital, Madrid, Spain
| | - A Gago-Veiga
- Neurology Department, La Princesa University Hospital, Madrid, Spain
| | - J Camiña
- Neurology Department, Rotger Clinic, Palma de Mallorca, Spain
| | - M Ruiz
- Neurology Department, San Juan Hospital, Alicante, Spain
| | - N Mas-Sala
- Neurology Department, Althaia Hospital, Red Asistencial Universitaria de Manresa, Spain
| | - S Bohórquez
- Neurology Department, Sabana University, Bogotá, Colombia
| | - V J Gallardo
- Neurology Department, Sabana University, Bogotá, Colombia
| | - P Pozo-Rosich
- Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain
| |
Collapse
|
39
|
Abstract
Liquid or blood-based biopsy is a less invasive and more efficient method in which to clinicians can identify diagnostic, prognostic, and therapeutic responsive biomarkers in cancer patients. Circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), RNAs, proteins, metabolites, and extracellular vesicles (EVs) are all potential biomarkers found in liquid biopsies. All nucleated cells including healthy, virally infected, and cancer cells release EVs. Since the early 1980s, evidence has mounted to support the pathophysiological role of EVs in cancer. Here we focus on the smallest of the EV, the exosome, and their clinical relevance as nanotherapeutics for cancers. Exosomes obtained from tumors have been reported to promote and/or facilitate malignancy of cancers especially in terms of metastatic potential. Exosomal EVs have also contributed to the development of therapeutic resistance. Recent studies demonstrate that intrinsic and bioengineered exosomes can serve as effective therapeutic agents that disrupt cancer progression. Here we review the current literature regarding the utilization of bioengineered exosomes for therapeutics to treat prevalent cancers such as melanoma, glioma, breast, pancreatic, hepatic, cervical, prostate, and colon cancers. Overall, studies reviewed show that bioengineered exosomes are effective and promising for targeted cancer therapy.
Collapse
Affiliation(s)
- J Miles
- Department of Immunology and NanoMedicine, Herbert Wertheim College of Medicine, Florida International University 11200 SW 8th Street Miami, FL 33199, USA
| | - M Andre
- Department of Immunology and NanoMedicine, Herbert Wertheim College of Medicine, Florida International University 11200 SW 8th Street Miami, FL 33199, USA
| | - A Caobi
- Department of Immunology and NanoMedicine, Herbert Wertheim College of Medicine, Florida International University 11200 SW 8th Street Miami, FL 33199, USA
| | - M Ruiz
- Department of Human and Health Services, Herbert Wertheim College of Medicine, Florida International University 11200 SW 8th Street Miami, FL 33199, USA; Miami Cancer Institute, Bone Marrow Transplant and CART T-Cell Therapy Department, Baptist Health South Florida, 8900 N Kendall Dr., Miami, FL 33176, USA
| | - M Nair
- Department of Immunology and NanoMedicine, Herbert Wertheim College of Medicine, Florida International University 11200 SW 8th Street Miami, FL 33199, USA
| | - Andrea D Raymond
- Department of Immunology and NanoMedicine, Herbert Wertheim College of Medicine, Florida International University 11200 SW 8th Street Miami, FL 33199, USA
| |
Collapse
|
40
|
Matrat L, Ruiz M, Dugelay E, Loras-Duclaux I, Marotte S, Heissat S, Sellier-Leclerc AL, Bacchetta J, Dubourg L, Peretti N. Alteration of renal function in children with long-term parenteral nutrition. Clin Nutr ESPEN 2020. [DOI: 10.1016/j.clnesp.2020.09.499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
41
|
Llopiz D, Ruiz M, Silva L, Repáraz D, Aparicio B, Egea J, Lasarte JJ, Redin E, Calvo A, Angel M, Berzofsky JA, Stroncek D, Sarobe P. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy. Cancer Lett 2020; 499:279-289. [PMID: 33232788 DOI: 10.1016/j.canlet.2020.11.022] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 11/05/2020] [Accepted: 11/16/2020] [Indexed: 01/19/2023]
Abstract
Analyzing immunomodulatory elements operating during antitumor vaccination in prostate cancer patients and murine models we identified IL-10-producing DC as a subset with poorer immunogenicity and clinical efficacy. Inhibitory TAM receptors MER and AXL were upregulated on murine IL-10+ DC. Thus, we analyzed conditions inducing these molecules and the potential benefit of their blockade during vaccination. MER and AXL upregulation was more efficiently induced by a vaccine containing Imiquimod than by a poly(I:C)-containing vaccine. Interestingly, MER expression was found on monocyte-derived DC, and was dependent on IL-10. TAM blockade improved Imiquimod-induced DC activation in vitro and in vivo, resulting in increased vaccine-induced T-cell responses, which were further reinforced by concomitant IL-10 inhibition. In different tumor models, a triple therapy (including vaccination, TAM inhibition and IL-10 blockade) provided the strongest therapeutic effect, associated with enhanced T-cell immunity and enhanced CD8+ T cell tumor infiltration. Finally, MER levels in DC used for vaccination in cancer patients correlated with IL-10 expression, showing an inverse association with vaccine-induced clinical response. These results suggest that TAM receptors upregulated during vaccination may constitute an additional target in combinatorial therapeutic vaccination strategies.
Collapse
MESH Headings
- Adjuvants, Immunologic/administration & dosage
- Animals
- CD8-Positive T-Lymphocytes/drug effects
- CD8-Positive T-Lymphocytes/immunology
- CD8-Positive T-Lymphocytes/metabolism
- Cancer Vaccines/administration & dosage
- Cancer Vaccines/immunology
- Cell Line, Tumor
- Dendritic Cells/drug effects
- Dendritic Cells/immunology
- Dendritic Cells/metabolism
- Female
- Gene Expression Regulation, Neoplastic/drug effects
- Gene Expression Regulation, Neoplastic/immunology
- Humans
- Imiquimod/administration & dosage
- Immunogenicity, Vaccine/drug effects
- Immunotherapy/methods
- Interleukin-10/metabolism
- Lymphocytes, Tumor-Infiltrating/drug effects
- Lymphocytes, Tumor-Infiltrating/immunology
- Lymphocytes, Tumor-Infiltrating/metabolism
- Male
- Melanoma, Experimental/immunology
- Melanoma, Experimental/pathology
- Melanoma, Experimental/therapy
- Mice
- Mice, Transgenic
- Poly I-C/administration & dosage
- Prostatic Neoplasms/immunology
- Prostatic Neoplasms/pathology
- Prostatic Neoplasms/therapy
- Proto-Oncogene Proteins/antagonists & inhibitors
- Proto-Oncogene Proteins/genetics
- Pyrimidines
- Quinolines
- Receptor Protein-Tyrosine Kinases/antagonists & inhibitors
- Receptor Protein-Tyrosine Kinases/genetics
- Up-Regulation/drug effects
- Up-Regulation/immunology
- c-Mer Tyrosine Kinase/antagonists & inhibitors
- c-Mer Tyrosine Kinase/genetics
- Axl Receptor Tyrosine Kinase
Collapse
Affiliation(s)
- Diana Llopiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Marta Ruiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Leyre Silva
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - David Repáraz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Belén Aparicio
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Josune Egea
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Juan J Lasarte
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - Esther Redin
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; CIBERONC, ISCIII, Madrid, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain
| | - Alfonso Calvo
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; CIBERONC, ISCIII, Madrid, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain
| | - Matthew Angel
- Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Center for Cancer Research Collaborative Bioinformatics Resource, Leidos Biomedical Research, Inc., FNLCR, Frederick, MD, USA
| | - Jay A Berzofsky
- Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - David Stroncek
- Center for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA
| | - Pablo Sarobe
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
| |
Collapse
|
42
|
Silva L, Egea J, Villanueva L, Ruiz M, Llopiz D, Repáraz D, Aparicio B, Lasarte-Cia A, Lasarte JJ, Ruiz de Galarreta M, Lujambio A, Sangro B, Sarobe P. Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses Against Hepatocellular Carcinoma. Cancers (Basel) 2020; 12:cancers12113397. [PMID: 33207844 PMCID: PMC7696968 DOI: 10.3390/cancers12113397] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 11/11/2020] [Accepted: 11/11/2020] [Indexed: 02/06/2023] Open
Abstract
Therapies based on immune checkpoint inhibitors (ICPI) have yielded promising albeit limited results in patients with hepatocellular carcinoma (HCC). Vaccines have been proposed as combination partners to enhance response rates to ICPI. Thus, we analyzed the combined effect of a vaccine based on the TLR4 ligand cold-inducible RNA binding protein (CIRP) plus ICPI. Mice were immunized with vaccines containing ovalbumin linked to CIRP (OVA-CIRP), with or without ICPI, and antigen-specific responses and therapeutic efficacy were tested in subcutaneous and orthotopic mouse models of liver cancer. OVA-CIRP elicited polyepitopic T-cell responses, which were further enhanced when combined with ICPI (anti-PD-1 and anti-CTLA-4). Combination of OVA-CIRP with ICPI enhanced ICPI-induced therapeutic responses when tested in subcutaneous and intrahepatic B16-OVA tumors, as well as in the orthotopic PM299L HCC model. This effect was associated with higher OVA-specific T-cell responses in the periphery, although many tumor-infiltrating lymphocytes still displayed an exhausted phenotype. Finally, a new vaccine containing human glypican-3 linked to CIRP (GPC3-CIRP) induced clear responses in humanized HLA-A2.01 transgenic mice, which increased upon combination with ICPI. Therefore, CIRP-based vaccines may generate anti-tumor immunity to enhance ICPI efficacy in HCC, although blockade of additional checkpoint molecules and immunosuppressive targets should be also considered.
Collapse
Affiliation(s)
- Leyre Silva
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; (L.S.); (J.E.); (L.V.); (M.R.); (D.L.); (D.R.); (B.A.); (A.L.-C.); (J.J.L.)
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBEREHD, 31008 Pamplona, Spain
| | - Josune Egea
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; (L.S.); (J.E.); (L.V.); (M.R.); (D.L.); (D.R.); (B.A.); (A.L.-C.); (J.J.L.)
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBEREHD, 31008 Pamplona, Spain
| | - Lorea Villanueva
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; (L.S.); (J.E.); (L.V.); (M.R.); (D.L.); (D.R.); (B.A.); (A.L.-C.); (J.J.L.)
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
| | - Marta Ruiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; (L.S.); (J.E.); (L.V.); (M.R.); (D.L.); (D.R.); (B.A.); (A.L.-C.); (J.J.L.)
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBEREHD, 31008 Pamplona, Spain
| | - Diana Llopiz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; (L.S.); (J.E.); (L.V.); (M.R.); (D.L.); (D.R.); (B.A.); (A.L.-C.); (J.J.L.)
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBEREHD, 31008 Pamplona, Spain
| | - David Repáraz
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; (L.S.); (J.E.); (L.V.); (M.R.); (D.L.); (D.R.); (B.A.); (A.L.-C.); (J.J.L.)
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBEREHD, 31008 Pamplona, Spain
| | - Belén Aparicio
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; (L.S.); (J.E.); (L.V.); (M.R.); (D.L.); (D.R.); (B.A.); (A.L.-C.); (J.J.L.)
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBEREHD, 31008 Pamplona, Spain
| | - Aritz Lasarte-Cia
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; (L.S.); (J.E.); (L.V.); (M.R.); (D.L.); (D.R.); (B.A.); (A.L.-C.); (J.J.L.)
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
| | - Juan José Lasarte
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; (L.S.); (J.E.); (L.V.); (M.R.); (D.L.); (D.R.); (B.A.); (A.L.-C.); (J.J.L.)
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
| | - Marina Ruiz de Galarreta
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; (M.R.d.G.); (A.L.)
| | - Amaia Lujambio
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; (M.R.d.G.); (A.L.)
| | - Bruno Sangro
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBEREHD, 31008 Pamplona, Spain
- Liver Unit, Clínica Universidad de Navarra, 31008 Pamplona, Spain
| | - Pablo Sarobe
- Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; (L.S.); (J.E.); (L.V.); (M.R.); (D.L.); (D.R.); (B.A.); (A.L.-C.); (J.J.L.)
- IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain;
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBEREHD, 31008 Pamplona, Spain
- Correspondence: ; Tel.: +34-948-194700 (ext. 813009)
| |
Collapse
|
43
|
Liberatore G, Manganelli F, Doneddu PE, Cocito D, Fazio R, Briani C, Filosto M, Benedetti L, Mazzeo A, Antonini G, Cosentino G, Jann S, Cortese A, Marfia GA, Clerici AM, Siciliano G, Carpo M, Luigetti M, Lauria G, Rosso T, Cavaletti G, Santoro L, Peci E, Tronci S, Ruiz M, Cotti Piccinelli S, Schenone A, Leonardi L, Toscano A, Mataluni G, Spina E, Gentile L, Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria? Eur J Neurol 2020; 28:620-629. [PMID: 32959475 DOI: 10.1111/ene.14545] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Revised: 09/10/2020] [Accepted: 09/11/2020] [Indexed: 12/14/2022]
Abstract
BACKGROUND AND PURPOSE The aim was to identify the clinical and diagnostic investigations that may help to support a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in patients not fulfilling the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS) electrodiagnostic criteria. METHODS The data from patients with a clinical diagnosis of CIDP included in a national database were retrospectively reviewed. RESULTS In all, 535 patients with a diagnosis of CIDP were included. This diagnosis fulfilled the EFNS/PNS criteria in 468 patients (87.2%) (definite in 430, probable in 33, possible in three, while two had chronic immune sensory polyradiculopathy). Sixty-seven patients had a medical history and clinical signs compatible with CIDP but electrodiagnostic studies did not fulfill the EFNS/PNS criteria for CIDP. These patients had similar clinical features and frequency of abnormal supportive criteria for the diagnosis of CIDP compared to patients fulfilling EFNS/PNS criteria. Two or more abnormal supportive criteria were present in 40 (61.2%) patients rising to 54 (80.6%) if a history of a relapsing course as a possible supportive criterion was also included. Increased cerebrospinal fluid proteins and response to immune therapy most frequently helped in supporting the diagnosis of CIDP. Response to therapy was similarly frequent in patients fulfilling or not EFNS/PNS criteria (87.3% vs. 85.9%). CONCLUSIONS Patients with a clinical diagnosis of CIDP had similar clinical findings, frequency of abnormal supportive criteria and response to therapy compared to patients fulfilling EFNS/PNS criteria. The presence of abnormal supportive criteria may help in supporting the diagnosis of CIDP in patients with a medical history and clinical signs compatible with this diagnosis but non-diagnostic nerve conduction studies.
Collapse
Affiliation(s)
- G Liberatore
- Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Clinical and Research Institute, Milan, Italy
| | - F Manganelli
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Naples, Italy
| | - P E Doneddu
- Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Clinical and Research Institute, Milan, Italy
| | - D Cocito
- Presidio Sanitario Major, Istituti Clinici Scientifici Maugeri, Turin, Italy
| | - R Fazio
- Department of Neurology, Division of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy
| | - C Briani
- Neurology Unit, Department of Neuroscience, University of Padova, Padova, Italy
| | - M Filosto
- Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy
| | - L Benedetti
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy.,Neurology Unit, Sant'Andrea Hospital, La Spezia, Italy
| | - A Mazzeo
- Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy
| | - G Antonini
- Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sant'Andrea Hospital, 'Sapienza' University of Rome, Rome, Italy
| | - G Cosentino
- Department of Experimental BioMedicine and Clinical Neurosciences (BioNeC), University of Palermo, Palermo, Italy.,IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy.,Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - S Jann
- Department of Neuroscience, Niguarda Ca' Granda Hospital, Milan, Italy
| | - A Cortese
- IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy.,Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.,Molecular Neurosciences, University College London, London, UK
| | - G A Marfia
- Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy
| | - A M Clerici
- Neurology Unit, Circolo and Macchi Foundation Hospital, Insubria University, DBSV, Varese, Italy
| | - G Siciliano
- Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - M Carpo
- Neurology Unit, ASST Bergamo Ovest-Ospedale Treviglio, Treviglio, Italy
| | - M Luigetti
- Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - G Lauria
- Unit of Neuroalgology, IRCCS Foundation 'Carlo Besta' Neurological Institute, Milan, Italy.,Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Milan, Italy
| | - T Rosso
- ULSS2 Marca Trevigiana, UOC Neurologia-Castelfranco Veneto, Treviso, Italy
| | - G Cavaletti
- School of Medicine and Surgery and Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy
| | - L Santoro
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Naples, Italy
| | - E Peci
- Presidio Sanitario Major, Istituti Clinici Scientifici Maugeri, Turin, Italy
| | - S Tronci
- Department of Neurology, Division of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy
| | - M Ruiz
- Neurology Unit, Department of Neuroscience, University of Padova, Padova, Italy
| | - S Cotti Piccinelli
- Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy
| | - A Schenone
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy
| | - L Leonardi
- Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sant'Andrea Hospital, 'Sapienza' University of Rome, Rome, Italy
| | - A Toscano
- Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy
| | - G Mataluni
- Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy
| | - E Spina
- Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Naples, Italy
| | - L Gentile
- Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy
| | - E Nobile-Orazio
- Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Clinical and Research Institute, Milan, Italy.,Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy
| | | |
Collapse
|
44
|
Doneddu PE, Cocito D, Manganelli F, Fazio R, Briani C, Filosto M, Benedetti L, Bianchi E, Jann S, Mazzeo A, Antonini G, Cosentino G, Marfia GA, Cortese A, Clerici AM, Carpo M, Schenone A, Siciliano G, Luigetti M, Lauria G, Rosso T, Cavaletti G, Beghi E, Liberatore G, Santoro L, Spina E, Peci E, Tronci S, Ruiz M, Cotti Piccinelli S, Verrengia EP, Gentile L, Leonardi L, Mataluni G, Piccolo L, Nobile-Orazio E. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry 2020; 91:1092-1099. [PMID: 32868387 DOI: 10.1136/jnnp-2020-323615] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 08/01/2020] [Accepted: 08/06/2020] [Indexed: 12/24/2022]
Abstract
OBJECTIVES To determine the prevalence of different comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and their impact on outcome, treatment choice and response. METHODS Using a structured questionnaire, we collected information on comorbidities from 393 patients with CIDP fulfilling the European Federation of Neurological Societies and Peripheral Nerve Society criteria included in the Italian CIDP database. RESULTS One or more comorbidities were reported by 294 patients (75%) and potentially influenced treatment choice in 192 (49%) leading to a less frequent use of corticosteroids. Response to treatment did not differ, however, from that in patients without comorbidities. Diabetes (14%), monoclonal gammopathy of undetermined significance (MGUS) (12%) and other immune disorders (16%) were significantly more frequent in patients with CIDP than expected in the general European population. Patients with diabetes had higher disability scores, worse quality of life and a less frequent treatment response compared with patients without diabetes. Patients with IgG-IgA or IgM MGUS had an older age at CIDP onset while patients with other immune disorders had a younger age at onset and were more frequently females. IgM MGUS was more frequent in patients with motor CIDP than in patients with typical CIDP. CONCLUSIONS Comorbidities are frequent in patients with CIDP and in almost 50% of them have an impact on treatment choice. Diabetes, MGUS and other immune diseases are more frequent in patients with CIDP than in the general population. Only diabetes seems, however, to have an impact on disease severity and treatment response possibly reflecting in some patients a coexisting diabetic neuropathy.
Collapse
Affiliation(s)
- Pietro Emiliano Doneddu
- Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy
| | - Dario Cocito
- Divisione di Riabilitazione Neuromotoria, Istituti Clinici Scientifici Maugeri - Presidio Sanitario Major, Torino, Italy
| | - Fiore Manganelli
- Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II of Naples, Naples, Italy
| | - Raffaella Fazio
- Department of Neurology, San Raffaele Hospital Institute of Experimental Neurology, Milano, Lombardia, Italy
| | - Chiara Briani
- Department of Neuroscience, University of Padua, Padova, Italy
| | | | - Luana Benedetti
- Department of Neurology, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - Elisa Bianchi
- Laboratorio di Malattie Neurologiche, IRCCS-Istituto Mario Negri, Milano, Italy
| | - Stefano Jann
- Department of Neuroscience, Niguarda Ca' Granda Hospital, Milano, Italy
| | - Anna Mazzeo
- Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy
| | - Giovanni Antonini
- Department of Neurology Mental Health and Sensory Organs (NESMOS), 'Sapienza' University of Rome, Sant' Andrea Hospital, Roma, Italy
| | - Giuseppe Cosentino
- Department of Neurology, University of Pavia, IRCCS Mondino Foundation, Pavia, Italy
| | | | - Andrea Cortese
- Department of Neurology, University of Pavia, IRCCS Mondino Foundation, Pavia, Italy
| | | | - Marinella Carpo
- Department of Neurology, ASST Bergamo Ovest-Ospedale Treviglio, Treviglio, Italy
| | - Angelo Schenone
- Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy
| | - Gabriele Siciliano
- Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Marco Luigetti
- UOC Neurologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.,Dipartimento di scienze dell'invecchiamento, neurologiche, ortopediche e della testa-collo, Universita Cattolica del Sacro Cuore Sede di Roma, Roma, Italy
| | - Giuseppe Lauria
- Unit of Neuroalgology, Foundation IRCCS Carlo Besta Neurological Institute, Milano, Italy.,Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Milano, Italy
| | - Tiziana Rosso
- UOC Neurologia-Castelfranco Veneto, ULSS2 Marca Trevigiana, Treviso, Italy
| | - Guido Cavaletti
- School of Medicine and Surgery and Experimental Neurology Unit, Universita degli Studi di Milano-Bicocca, Milano, Italy
| | - Ettore Beghi
- Laboratorio di Malattie Neurologiche, IRCCS-Istituto Mario Negri, Milano, Italy
| | - Giuseppe Liberatore
- Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy
| | - Lucio Santoro
- Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II of Naples, Naples, Italy
| | - Emanuele Spina
- Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II of Naples, Naples, Italy
| | - Erdita Peci
- Department of Neuroscience, University of Turin, Torino, Italy
| | - Stefano Tronci
- Department of Neurology, San Raffaele Hospital Institute of Experimental Neurology, Milano, Lombardia, Italy
| | - Marta Ruiz
- Department of Neuroscience, University of Padua, Padova, Italy
| | | | | | - Luca Gentile
- Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy
| | - Luca Leonardi
- Department of Neurology Mental Health and Sensory Organs (NESMOS), 'Sapienza' University of Rome, Sant' Andrea Hospital, Roma, Italy
| | - Giorgia Mataluni
- Department of Systems Medicine, Univeristy of Roma Tor Vergata, Rome, Italy
| | - Laura Piccolo
- Department of Neurology, University of Pavia, IRCCS Mondino Foundation, Pavia, Italy
| | - Eduardo Nobile-Orazio
- Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy .,Department of Medical Biotechnology and Translational Medicine, University of Milan, Milano, Lombardia, Italy
| | | |
Collapse
|
45
|
Copetti M, Rollot F, Clement A, Ruiz M, Guéry M, Pellegrini F. Comparaison en vie réelle du diméthylfumarate versus fingolimod dans la sclérose en plaques (SEP) à partir de la cohorte OFSEP. Rev Neurol (Paris) 2020. [DOI: 10.1016/j.neurol.2020.01.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Hevia V, Lorca J, Hevia M, Domínguez A, López-Plaza J, Artiles A, Álvarez S, Sánchez Á, Fraile A, López-Fando L, Sanz E, Ruiz M, Alcaraz E, Burgos FJ. [COVID-19 Pandemic: Impact and rapid reaction of Urology]. Actas Urol Esp 2020; 44:450-457. [PMID: 38620218 PMCID: PMC7181986 DOI: 10.1016/j.acuro.2020.04.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Accepted: 04/21/2020] [Indexed: 01/08/2023]
Abstract
The COVID-19 pandemic caused by the SARS-CoV-2 virus has caused tens of thousands of deaths in Spain and has managed to breakdown the healthcare system hospitals in the Community of Madrid, largely due to its tendency to cause severe pneumonia, requiring ventilatory support. This fact has caused our center to collapse, with 130% of its beds occupied by COVID-19 patients, thus causing the absolute cessation of activity of the urology service, the practical disappearance of resident training programs, and the incorporation of a good part of the urology staff into the group of medical personnel attending these patients. In order to recover from this extraordinary level of suspended activity, we will be obliged to prioritize pathologies based on purely clinical criteria, for which tables including the relevance of each pathology within each area of urology are being proposed. Technology tools such as online training courses or surgical simulators may be convenient for the necessary reestablishment of resident education.
Collapse
Affiliation(s)
- V Hevia
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - J Lorca
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - M Hevia
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - A Domínguez
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - J López-Plaza
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - A Artiles
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - S Álvarez
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - Á Sánchez
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - A Fraile
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - L López-Fando
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - E Sanz
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - M Ruiz
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| | - E Alcaraz
- Área de Diagnóstico Urológico y Pruebas Instrumentales de Urología, Servicio de Urología, Hospital Universitario Ramón y Cajal, Madrid, España
| | - F J Burgos
- Servicio de Urología, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
| |
Collapse
|
47
|
Yendewa GA, Sahr F, Lakoh S, Ruiz M, Patiño L, Tabernilla A, Deen GF, Sesay M, Salata RA, Poveda E. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone. J Antimicrob Chemother 2020; 74:2024-2029. [PMID: 30989237 PMCID: PMC6587425 DOI: 10.1093/jac/dkz134] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2019] [Revised: 02/27/2019] [Accepted: 03/06/2019] [Indexed: 11/15/2022] Open
Abstract
Objectives The aim of this study was to assess the prevalence of HIV drug resistance (HIVDR) in HIV-infected ART-naive and -experienced patients in Sierra Leone. Patients and methods We conducted a cross-sectional study of HIV-positive adults aged ≥18 years at Connaught Hospital in Freetown, Sierra Leone in November 2017. Sequencing was performed in the reverse transcriptase, protease and integrase regions, and interpreted using the Stanford HIVDR database and WHO 2009 mutation list. Results Two hundred and fifteen HIV-infected patients were included (64 ART naive and 151 ART experienced). The majority (66%) were female, the median age was 36 years and the median ART exposure was 48 months. The majority (83%) were infected with HIV-1 subtype CRF02_AG. In the ART-naive group, the pretreatment drug resistance (PDR) prevalence was 36.7% (14.2% to NRTIs and 22.4% to NNRTIs). The most prevalent PDR mutations were K103N (14.3%), M184V (8.2%) and Y181C (4.1%). In the ART-experienced group, 64.4% harboured resistance-associated mutations (RAMs) and the overall prevalence of RAMs to NRTIs and NNRTIs was 85.2% (52/61) and 96.7% (59/61), respectively. The most prevalent RAMs were K103N (40.7%), M184V (28.8%), D67N (15.3%) and T215I/F/Y (15.3%). Based on the genotypic susceptibility score estimates, 22.4% of ART-naive patients and 56% of ART-experienced patients were not susceptible to first-line ART used in Sierra Leone. Conclusions A high prevalence of circulating NRTI- and NNRTI-resistant variants was observed in ART-naive and -experienced HIV-1-infected patients in Sierra Leone. This necessitates the implementation of HIVDR surveillance programmes to inform national ART guidelines for the treatment and monitoring of HIV-infected patients in Sierra Leone.
Collapse
Affiliation(s)
- George A Yendewa
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.,Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.,Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Foday Sahr
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | - Sulaiman Lakoh
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | - Marta Ruiz
- Group of Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, Spain
| | - Lucia Patiño
- Group of Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, Spain
| | - Andrés Tabernilla
- Group of Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, Spain
| | - Gibrilla F Deen
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | - Momodu Sesay
- National HIV/AIDS Secretariat, Freetown, Sierra Leone
| | - Robert A Salata
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.,Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - Eva Poveda
- Group of Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, Spain
| |
Collapse
|
48
|
Soler-Garcia A, Gamell A, Santiago B, Monsonís M, Calvo C, Cobo E, Colino E, Espiau M, Guerrero-Laleona C, Lobato Z, Martín-Nalda A, Pérez-Gorricho B, Perez-Porcuna TM, Piqueras AI, Rodríguez-Molino P, Ruiz M, Soriano-Arandes A, Valmanya T, Tebruegge M, Noguera-Julian A, Gómez-Pastrana D, Montero M, Peromingo E, Bustillo M, Moliner E, Fenoy M, Velásquez M, Soler MQ, GARCÍA L, Calavia O, Rius N, Pascual MT, Soler-Palacín P, Tórtola T, Lillo M, Dapena M, López-Medina EM, Ruiz M, Santos MDM, Hernández Á, Hernández-Sanpelayo T, Tagarro A, Méndez A, Mellado MJ, Baquero-Artigao F, Sainz T, García-Hortelano M, Álvarez J, Villalobos E, García-García ML, Garrote MI, Korta Murua JJ, Gundín NA, Sánchez-Torrent L, Velasco-Arnaiz E, Fortuny C. Diagnostic Accuracy of QuantiFERON-TB Gold Plus Assays in Children and Adolescents with Tuberculosis Disease. J Pediatr 2020; 223:212-215.e1. [PMID: 32334890 DOI: 10.1016/j.jpeds.2020.02.025] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Revised: 01/27/2020] [Accepted: 02/12/2020] [Indexed: 10/24/2022]
Abstract
In 2016, a new interferon-gamma release assay, QuantiFERON-TB Gold Plus, was introduced. We conducted a cross-sectional multicenter study, involving 158 children and adolescents with tuberculosis disease. The overall sensitivity of the assay was 82.9% (IQR 77.0%-88.8%), indicating that in children this test does not have higher sensitivity than previous generation interferon-gamma release assays.
Collapse
Affiliation(s)
- Aleix Soler-Garcia
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d´Infeccions, Servei de Pediatria, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, Barcelona, Spain
| | - Anna Gamell
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d´Infeccions, Servei de Pediatria, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, Barcelona, Spain
| | - Begoña Santiago
- Pediatric Infectious Diseases Unit, Gregorio Marañón Hospital, Madrid, Spain
| | - Manuel Monsonís
- Servei de Microbiologia, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Cristina Calvo
- Pediatrics Department, Hospital Severo Ochoa, Madrid, Spain; Pediatric Infectious and Tropical Diseases Department, Hospital La Paz, Madrid, Spain; Health Research Institute IdiPAZ, Hospital La Paz, Madrid, Spain; Red de Investigación Translacional en Infectología Pediátrica, RITIP, Madrid, Spain
| | - Elvira Cobo
- Pediatric Infectious Diseases Unit, Gregorio Marañón Hospital, Madrid, Spain
| | - Elena Colino
- Pediatrics Department, Complejo Hospitalario Universitario Insular-Materno Infantil de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - María Espiau
- Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Carmelo Guerrero-Laleona
- Unidad de Enfermedades Infecciosas, Servicio de Pediatría, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - Zulema Lobato
- Servei de Pediatria, Hospital Sant Joan de Déu, Fundació Althaia, Manresa, Spain
| | - Andrea Martín-Nalda
- Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Beatriz Pérez-Gorricho
- Pediatric Infectious Diseases Unit, Department of Pediatrics, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | - Tomas M Perez-Porcuna
- Atenció Primària, Fundació Assistencial Mútua Terrassa, Terrassa, Spain; Unitat de Salut Internacional, Departament de Pediatria, Fundació Recerca Mútua Terrassa, Atenció Primària, Hospital Universitari Mútua de Terrassa, Universitat de Barcelona, Terrassa, Spain
| | - Ana Isabel Piqueras
- Pediatric Infectious Diseases Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | | | - Marta Ruiz
- Pediatrics Department, Hospital de Getafe, Madrid, Spain
| | - Antoni Soriano-Arandes
- Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Teresa Valmanya
- Servei de Pediatria, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - Marc Tebruegge
- Department of Pediatric Infectious Diseases & Immunology, Evelina London Childrenś Hospital, Guyś and St. Thomaś NHS Foundation Trust, London, United Kingdom; Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom; Department of Pediatrics, University of Melbourne, Parkville, Australia
| | - Antoni Noguera-Julian
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d´Infeccions, Servei de Pediatria, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, Barcelona, Spain; Red de Investigación Translacional en Infectología Pediátrica, RITIP, Madrid, Spain; Departament de Pediatria, Universitat de Barcelona, Barcelona, Spain; CIBER de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Vega J, Castro R, Dormido-Canto S, Rattá G, Ruiz M. Automatic recognition of plasma relevant events: Implications for ITER. Fusion Engineering and Design 2020. [DOI: 10.1016/j.fusengdes.2020.111638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
50
|
Molina R, Porras-Segovia A, Ruiz M, Baca-García E. eHealth tools for assessing psychomotor activity in schizophrenia: a systematic review. ACTA ACUST UNITED AC 2020; 43:102-107. [PMID: 32555981 PMCID: PMC7861176 DOI: 10.1590/1516-4446-2019-0867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Accepted: 02/12/2020] [Indexed: 11/22/2022]
Abstract
Objective: Psychomotor abnormalities are relevant symptoms in the clinical presentation of schizophrenia, and assessing them could facilitate monitoring. New technologies can measure psychomotor activity objectively and continuously, but evidence on the topic is scarce. Our aim is to systematically review the existing evidence about eHealth tools for assessing psychomotor activity in patients diagnosed with schizophrenia. Method: We performed a systematic search of the PubMed and Embase databases and identified 15 relevant articles on eHealth tools for assessing psychomotor activity in schizophrenia. Results: eHealth devices accurately assessed psychomotor activity and were well accepted. Abnormalities in psychomotor activity helped differentiate between different subtypes of schizophrenia. Abnormal increases in psychomotor activity were correlated with acute presentations, while lower activity was associated with relapses, deterioration, and negative symptoms. Conclusion: Actigraphy is still the preferred eHealth device in research settings, but mobile applications have great potential. Further studies are needed to explore the possibilities of psychomotor monitoring and mobile health applications for preventing relapses in schizophrenia. eHealth could be useful for monitoring psychomotor activity, which might help prevent relapses.
Collapse
Affiliation(s)
- Rosa Molina
- Departamento de Psiquiatría, Hospital Universitario Rey Juan Carlos, Móstoles, Spain
| | | | - Marta Ruiz
- Departamento de Psiquiatría, Hospital Universitario Rey Juan Carlos, Móstoles, Spain
| | - Enrique Baca-García
- Departamento de Psiquiatría, Hospital Universitario Rey Juan Carlos, Móstoles, Spain.,Departamento de Psiquiatría, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,Departamento de Psiquiatría, Universidad Autonóma de Madrid, Madrid, Spain.,Departamento de Psiquiatría, Hospital General de Villalba, Madrid, Spain.,Departamento de Psiquiatría, Hospital Universitario Infanta Elena, Valdemoro, Spain.,Centro de Investigación Biomédica en Red Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.,Département de Psychiatrie, Centre Hospitalier Universitaire De Nîmes, Nîmes, France.,Universidad Católica del Maule, Talca, Chile
| |
Collapse
|